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ABSTRACT 
CHARACTERIZATION OF FAM134B IN THE CONTEXT OF 
HEPATOCELLULAR CARCINOMA AND ENDOPLASMIC RETICULUM 
STRESS 
Mustafa Yılmaz 
M.Sc. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Öztürk 
August 2011, 98 Pages 
 
Family with sequence similarity 134, member B (FAM134B) is a replicative 
senescence associated gene, previously identified in studies of our group as a result 
of microarray analysis in spontaneously senescent clones of Huh7 hepatocellular 
carcinoma cell line and their immortal counterparts. Originating from this finding, 
this study primarily focused on characterization of FAM134B in the context of 
hepatocellular carcinoma and endoplasmic reticulum stress. At the beginning, the 
relationship between senescence and FAM134B was experimented by inducing 
premature senescence in Huh7 cells. Adriamycin or TGF-β induced premature 
senescence did not result in amplification of FAM134B gene expression, suggesting 
that upregulation of FAM134B expression in spontaneous replicative senescence is 
not directly associated with a senescence phenotype. Then, FAM134B mRNA and 
protein levels were analyzed in both well- and poorly-differentiated HCC cell lines. 
Results showed that FAM134B expression is greater in poorly-differentiated cell 
lines, which represent advanced and metastatic HCC in vitro. On the other hand, our 
studies on the relationship between FAM134B and endoplasmic reticulum (ER) 
stress showed that FAM134B is an ER stress response gene, whose expression is 
upregulated by induction of ER stress with chemicals, such as thapsigargin, 
tunicamycin or DTT. Therefore, high protein and mRNA levels of FAM134B in 
poorly-differentiated cell lines are linked to the presence of a basal level ER stress 
response in this group of cell lines. Furthermore, overexpression studies in Huh7 
cells indicated that FAM134B cannot trigger an ER stress response or autophagic 
response in these cells. However, FAM134B was detected as an effector in cellular 
response, when ER stress is artificially induced by thapsigargin or tunicamycin 
treatments. FAM13B4 overexpression in Huh7 resulted in increased sensitivity to 
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thapsigargin or tunicamycin induced apoptosis. Moreover, increased FAM134B 
expression was also associated with decreased proliferative capacity in response to 
ER stress induction with the same chemicals. Consequently, FAM134B was 
suggested to affect the severity of stress in the ER when ER stress is started with an 
inducer. In addition, our tissue based experiments revealed that FAM134B is 
expressed in the brain and liver. Taken together, FAM134B might be an important 
protein contributing to the liver tissue damage and pathogenesis of HCC.  
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ÖZET 
FAM134B’NİN KARACİĞER KANSERİ VE ENDOPLAZMİK RETİKULUM 
STRESİ KONULARINDAKi ÖZELLİKLERİNİN BELİRLENMESİ 
Mustafa Yılmaz 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk 
Ağustos 2011, 98 Sayfa 
 
FAM134B (Family with sequence similarity 134, member B)’nin daha önceki 
çalışmalarımızda Huh7 karaciğer kanseri hücre hattında kendiliğinden gelişen hücre 
yaşlanmasında yapılan gen ifade profilleri analizi sonucunda hücre yaşlanmasıyla 
ilgili olduğunu tespit ettik. Bu bilgiden yola çıkarak bu çalışmada özellikle 
FAM134B’nin karaciğer kanseri ve endoplazmik retikulum stresi konuları 
çerçevesinde niteliklerinin belirlenmesini amaçladık. İlk olarak, hücre yaşlanması ve 
FAM134B ilişkisi Huh7 hücrelerinde erken hücre yaşlanmasına neden olarak test 
ettik. Adriamisin ve TGF-β kullanılarak sebep olunan erken hücre yaşlanması 
FAM134B gen ifadesinde artışa neden olmadı. Bu nedenle, kendiliğinden gelişen 
hücre yaşlanmasında görülen gen ifade artışının doğrudan hücre yağlanma 
fenotipiyle alakalı olmadı sonucuna vardık. Daha sonra, FAM134B’nin iyi 
diferansiye ve kötü diferansiye karaciğer kanseri hücre hatlarındaki mRNA ve 
protein seviyelerini analiz ettik. Sonuçlara göre, FAM134B ifadesi karaciğer 
kanserinin daha ileri aşamasını ve metastatik karakteristiğini temsil eden kötü 
diferansiye hücre hatlarında daha yüksektir. Diğer taraftan, FAM134B ve 
endoplazmik retikulum stres ilişkisi üzerinde yaptığımız araştırmalar, FAM134B’nin 
tapsigargin, tunikamisin ve DTT gibi endoplazmik retikulum stresine neden olan 
kimyasallarla gen ifadesinde artışla yanıt verdiğini tespit ettik. Bu nedenle, 
FAM134B’nin endoplazmik retikulum stresine yanıt veren bir gen olduğunu 
gösterdik. Bu sonuçla birlikte, kötü diferansiye hücre hatlarındaki yüksek FAM134B 
protein ve mRNA miktarlarını bu hücrelerdeki bazal seviyede endoplazmik 
retikulum stres yanıtıyla ilişkilendirdik. Ayrıca, bu geni yüksek seviyede ifade eden 
Huh7 hücrelerinde yaptığımız deneyler sonucunda FAM134B’nin kendi başına 
endoplazmik retikulum stres yanıtı ve otofajiye neden olamayacağını gösterdik. 
Ancak, tapsigargin ve tunikamisin kullanarak yapılan yapay endoplazmik retikulum 
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stresi durumunda FAM134B’nin hücre yanıtında etkili olduğunu gördük. Huh7 
hücrelerinde FAM134B geninin yüksek ifadesi tapsigargin ve tunikamisinin neden 
olduğu kontrollü hücre ölümü yanıtına duyarlılığı artırdığı sonucuna vardık. Ayrıca 
bu genin yüksek ifadesinin yine aynı şekilde endoplazmik retikulum stresi 
uygulandığı durumda hücrelerin çoğalma yeteneğini daha çok azalttığını gösterdik. 
Buna bağlı olarak, FAM134B, dışarıdan endoplazmik retikulum stresinin başlatıldığı 
durumlarda stresin şiddetinin artmasında rol oynadığını düşünmekteyiz. Bununla 
birlikte, dokular üzerinde yaptığımız çalışmada FAM134B ifadesinin beyin ve 
karaciğerde yoğun olduğunu gösterdik. Tüm bunlar göz önüne alındığında, 
FAM134B’nin karaciğer dokusunda biriken hasara ve böylece karaciğer kanserinin 
gelişimine etkili olma ihtimali vardır.   
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1. INTRODUCTION 
1.1 Hepatocellular carcinoma  
1.1.1 Epidemiology of hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the most common liver cancer type with a 
percentage between 80-90% among all primary liver cancer types. Furthermore, if all 
cancers are taken into consideration, HCC is classified in a substantial percentage, 
around 6% of all cancers (Parkin et al., 2005). HCC affects many populations in the 
world, taking a place among the most lethal cancers (Farazi and DePinho, 2006). 
After lung and stomach cancers, HCC is the third leading cause of cancer related 
deaths. It causes 600,000 deaths every year with a new occurrence of 500,000 – 
600,000 cases per year (Faloppi et al., 2011). Occurrence of HCC is directly related 
to age, having the highest frequency in the population of over age 65 (Gomaa et al., 
2008). Apart from the relationship between age and HCC, there is a significant sex 
ratio of 2,4:1, more common in men (Parkin et al., 2005).  
1.1.2 Aetiologies and risk factors of hepatocellular carcinoma 
Hepatocellular carcinoma is a cancer type with high complexity in terms of the 
aetiological factors leading to the occurrence of the hepatocarcinogenesis. Among 
these risk factors, the most major are viral factors such as chronic Hepatitis B and 
Hepatitis C, metabolic factors such as non-alcoholic fatty liver disease and diabetes, 
toxic factors such as aflatoxins and alcohol, immune related factors such as 
autoimmune hepatitis, and additional factors such as cirrhosis and hereditary 
haemochromatosis (Badvie, 2000; Farazi and DePinho, 2006; Parikh and Hyman, 
2007). Although all of these risk factors are associated with the incidence of HCC, 
effectiveness and the prevalence of these factors are highly dependent on the 
geographic condition over the world.  For instance, the difference in the geographical 
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distribution of HCC is mainly due to the variable distribution of Hepatitis B virus 
(HBV) and Hepatitis C virus (HCV) infections (Liu and Kao, 2007). However, even 
though HBV and HCV infections are important factors, they are not that much 
prominent in the US. Instead, alcoholic cirrhosis and dietary related non-alcoholic 
fatty liver diseases are the major factors leading hepatocarcinogenesis in most 
western countries (Stickel and Hellerbrand, 2010). 
1.1.2.1 Role of aflatoxin in hepatocarcinogenesis  
Aflatoxin B1 (AFB1) is a toxic factor for the liver produced by Aspergillus, which 
contaminate some foods, such as corn, peanut, and grain (Groopman et al., 1996). 
Therefore, digestion of such contaminated foods causes aflatoxin exposure in the 
liver and trigger hepatocarcinogenesis. The affect of aflatoxin on 
hepatocarcinogenesis is associated with its role in causing specific codon 249 
mutation on tumor suppressor p53 gene (Bressac et al., 1991; Ozturk, 1991). 
Interestingly, this mutation has also been detected in patients with a history of HBV 
infection (Yu et al., 2005). Hence, aflatoxin exposure is likely to trigger hepatocyte 
carcinogenesis by inducing a common mutation that is highly responsible for the lack 
of tumor suppression activity of p53.  
1.1.2.2 Role of alcohol in hepatocarcinogenesis 
Alcohol is metabolized mainly by activity of alcohol dehydrogenase enzyme in 
cytoplasm of hepatocytes, as well as by some other mechanisms in endoplasmic 
reticulum and peroxisomes (McKillop and Schrum, 2005). Ethanol metabolism 
results in products of free radicals and acetaldehyde. Release of these free radicals 
and acetaldehyde affects the cellular homeostasis by inducing oxidative stress and 
also preventing some cellular activities, such as DNA repair, by directly binding to 
the cellular components (Sun et al., 2001). On the other hand, ethanol directly affects 
the activities of some other key regulators of proliferation signaling and cell cycle, 
such as protein kinase C, adenylate cyclase, STAT, JNK, NF-ĸB, and MAPK 
(McKillop and Schrum, 2005) as well as increasing the activity of G protein inhibitor 
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which is associated with HCC through triggering p42/p44 MAPK signaling (Diehl, 
2005)      
1.1.2.3 Hepatitis B virus induced hepatocarcinogenesis 
Three decades ago, it has been shown that hepatitis B carriers have an increased 
annual incidence of HCC with an average of 0,5%, and 1% for population with age 
over 70 (Beasley et al., 1981). Further studies pointed out that HBV associated 
hepatocarcinogenesis is directly related to the necro-inflammation and fibrosis 
effects of this viral infection. These effects further pave the way for hepatocyte 
regeneration (Waris and Siddiqui, 2003). In addition, HBV infection can contribute 
to hepatocellular carcinogenesis through host genome integration, triggering some 
oncogenic pathways and even endoplasmic reticulum interaction and upregulation of 
oxidative stress (Farazi and DePinho, 2006). In terms of HBV and cirrhosis 
relationship, in East Asian countries, the incidence rate of HCC in HBV-related 
cirrhosis was shown to be 2,7% (Michielsen et al., 2005). This suggests that 
underlying liver diseases are undoubtedly key factors of acquiring HCC. In fact, 
HBV infection may also result in HCC independent of cirrhotic contribution, 
showing that not merely HBV and cirrhosis co-contribution but co-contribution of 
HBV with some other factors lead to hepatocarcinogenesis (Waris and Siddiqui, 
2003).  
1.1.2.4 Hepatitis C virus induced hepatocarcinogenesis  
Hepatitis C virus infection is associated with hepatocyte transformation in different 
ways. Firstly, studies showed that HCV infection is most likely to turn into chronic 
infection, because about 80% of the infected patients cannot be totally disinfected in 
the acute phase. Resulting chronic infection results in prevailing of the effects of 
viral infection, such as inflammation and regeneration in hepatocytes. These in 
advance lead to chronic hepatitis and cirrhosis, which finally brings out hepatocyte 
carcinogenesis with the accumulation of chromosomal abnormalities (Ahn and 
Flamm, 2004; Suruki et al., 2006). The percentage of cirrhosis development and 
hepatocellular carcinogenesis in the chronic infection cases are 20% and 2,5%, 
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respectively (Bowen and Walker, 2005). In addition, HCV induced 
hepatocarcinogenesis is found to involve some key viral proteins in promotion of 
carcinogenesis. Among these, NS5A is known to control transcription and mitogenic 
signal transduction as well as the regulation of cell cycle (Tellinghuisen and Rice, 
2002). Besides, important cell regulatory mechanisms, such as proliferation, 
apoptosis, transcription and key signaling factors of these regulations, such as NF-ĸB 
and MAP kinase are modulated by HCV core protein (Block et al., 2003). 
1.1.2.5 Other factors inducing hepatocarcinogenesis  
Apart from the major risk factors of hepatocellular carcinogenesis, there are some 
other aspects contributing to the initiation or development of HCC. 
Diabetes is considered as one of the key additional factors for the onset of HCC. 
Studies of Davila et al. showed that the ratio of HCC patients with diabetes is 
substantially greater than the patients with diabetes within the control group without 
cancer. Furthermore, independent of the other foremost risk factors, diabetes is 
regarded as a self-determining risk factor with an effect of 2-3 fold increase in 
occurrence of HCC (Davila et al., 2005). The link between diabetes and the 
hepatocellular carcinogenesis is possibly due to the accumulation of free fatty acids 
in liver and the acquisition of insulin resistance in the liver of diabetic patient 
(Maclaren et al., 2007). These results cause development of fibrosis through 
dysfunctional effects on hepatocyte homeostasis, such as hepatocyte injury and 
hepatocyte apoptosis (Farrell and Larter, 2006). 
Apart from the effect of diabetes on HCC, other disorders affecting liver are also 
involved in the increased risk of hepatocarcinogenesis. Among these, non-alcoholic 
steatohepatitis and non-alcoholic fatty liver disease are likely to promote HCC 
development in a way that they contribute to advance of liver fibrosis and cirrhosis 
(Adams and Angulo, 2005). Furthermore, some other genetic disorders, such as 
hereditary haemochromatosis and alpha1-antitrypsin deficiency are associated with 
the higher risk of developing HCC (Badvie, 2000). Hereditary haemochromatosis is a 
disease related to the excess iron taking into hepatocytes. Such an iron overload in 
hepatocytes brings about a hepatocellular damage, finally leading to 
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hepatocarcinogenesis (Pietrangelo, 2009). Another inherited disease alpha1-
antitrypsin deficiency comes up with the emergence of antitrypsin polymers in the 
liver cells. These antitrypsin polymers trigger hepatocyte fatality, and thereby, 
cirrhosis (Parfrey et al., 2003).    
1.1.3 Molecular pathogenesis of hepatocellular carcinoma 
It has been discussed that the molecular pathogenesis of hepatocellular carcinoma is 
a rather complex mechanism (Farazi and DePinho, 2006). Through the progress of 
HCC, different risk factors and modulations, such as mutation, altered pathways, 
genetic changes, epidgenetic changes, and chromosomal aberrations are involved. 
Accumulation of these changes through hepatocarcinogenesis paves the way for the 
development of neoplastic state in normal livers, non-cirrhotic livers and cirrhotic 
livers (Bruix and Sherman, 2005; Llovet et al., 2003). The basis of HCC originates 
initially from damaged hepatocytes which later on start proliferation and 
regeneration cycles. Increased regenerating activity of hepatocytes leads to the 
occurrence of cirrhosis and then dysplasia, finally to hepatocellular carcinoma with 
the help of addition effects and risk factors (Schlaeger et al., 2008). Nevertheless, 
details of the molecular events resulting in hepatocellular carcinoma are still not well 
known (Farazi and DePinho, 2006).  
Normal liver to hepatocarcinogenic liver transition is a multistep mechanism mostly 
triggered by genetic changes resulting in firstly cirrhotic liver, and then cancer. This 
progress involves liver stem cells as well as hepatocytes (Llovet and Bruix, 2008). At 
the initial steps, HBV and HCV infections, amplified transforming growth factor 
alpha and insulin like growth factor 2 activities speeds up the early process of 
hepatocyte proliferation (Thorgeirsson and Grisham, 2002). During these stages, 
especially infection of HBV brings about oncogene activation, instable chromosomes 
and DNA rearrangements via integration of the viral genome (Ferber et al., 2003). 
On the other hand, DNA damage is further induced by occurrence of oxidative stress 
and chronic inflammation in hepatocytes (Hussain et al., 2007). At the preneoplastic 
stage of carcinogenesis, the process involves both genetic an epigenetic aberrations. 
In the mean time, dysplastic nodules are produced in a way that particular cell 
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populations with these aberrations are selected and grow up to form these dysplastic 
structures. This transformation is further supported by activation of survival and 
proliferation pathways, in addition to uncontrolled telomerase activity in order to 
serve for unlimited proliferative capacity of these cell populations (Llovet and Bruix, 
2008). Dysplastic nodules are pre-malignant structures possessing abnormalities at 
the cellular level and are likely to transform into hepatocellular carcinoma thanks to 
the accumulation of genomic instability and loss of p53 function (Farazi and 
DePinho, 2006).  
1.1.4 Genetics of hepatocellular carcinoma  
As other cancer types, hepatocellular carcinoma is also highly associated with the 
genetic aberrations in the original cells. These aberrations involve changes in gene 
expression, somatic mutations, amplification or deletion of specific sites and 
epigenetic changes directly affecting the expression of key genes (Llovet and Bruix, 
2008). Among these changes, genome wide alterations consisting of amplification or 
deletion of specific chromosomal sites have been detected in HCC cases. The most 
common amplification sites are 1q, 6p, 8q, 17q, and 20q, whereas deletion sites are 
4q, 8p, 13q, 16q, and 17p (Chiang et al., 2008a; Thorgeirsson and Grisham, 2002). 
Besides, other critical amplification sites were detected at regions where cyclin D1 
and VEGFA genes are located, at 11q13 and 6p21 sites, respectively (Chiang et al., 
2008a). There are a few critical somatic mutations already found to be associated 
with hepatocarcinogenesis. One of the major tumor suppressors, TP53 gene, was 
found to be mutated with a frequency of 30% in HCC patients worldwide. And, this 
mutation at the codon 249 of TP53 gene was reported to be related to aflatoxin B1 
exposure (Bressac et al., 1991). Besides, another cell cycle control gene Rb which is 
located at 13q site, which is a common loss of heterozygosity site, and inactivating 
mutations of Rb gene was reported to be at least 15% of HCC cases (Ozturk, 1999). 
In the aspect of genomic instability, the major alteration in the HCC cells is that 
hapatocarcinogenic cells have highly increased telomerase activity, approximately in 
90% of HCC cases. Increased telomerase activity is most likely due to HBV genome 
integration into TERT locus, increased expression of telomerase RNA component 
7 
 
TERC, and loss of a chromosomal region involving telomerase repressor (Farazi et 
al., 2003). In addition to genetic alterations, epigenetic changes are also factors in 
promoting hepatocarcinogenesis. Expressions of some critical genes having tumor 
suppressor roles, such as p16INK4a, E-cadherin, BRCA1, and IGFR-II, are 
suppressed by hypermethylation of the promoter regions of these genes (Farazi and 
DePinho, 2006; Thorgeirsson and Grisham, 2002).  
1.2 Senescence 
1.2.1 Cellular senescence 
Cellular senescence was first explained as a loss of proliferating ability of the cells in 
culture, resulting in the stop of population growth after an approximate number of 
passaging cells in vitro (Sherwood et al., 1988). Besides, cells with dividing and 
renewal ability can quit the cell cycle permanently due to various stress factors, such 
as DNA damage, mitogenic signals, change in the chromatin structure and 
dysfunctional telomeres (Campisi, 2005). Cellular senescence is a potential anti-
cancer mechanism mainly regulated through p53 and RB proteins. Senescence 
response acts as a barrier for cancer in a way that damaged cells are prevented from 
aberrant proliferation which is a key factor of carcinogenesis (Campisi, 2005). 
However, senescent cells undergo significant changes at the cellular level, such as 
chromosomal aberrations, increased size and size heterogeneity (Sherwood et al., 
1988). And, these changes at the cellular level may contribute to aging and some age 
related diseases (Campisi, 2005). 
1.2.2 Replicative senescence  
Replicative senescence refers to the induction of senescence response as a result of 
telomere shortening. Telomeres are repetitive hexamer units located at the ends of 
eukaryotic chromosomes. These structures act as caps for the linear end, having a 
length of a few to several kbs. Presence of telomeres at the end of chromosomes 
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provides protection against chromosomal degradation and chromosome end fusion 
(Reaper et al., 2004).  
Telomere dependent senescence is associated with the telomere shortening. In the 
lack of adequate telomerase activity, a part of telomeres are lost during the 
replication process. Loss of telomeres in each replication results in drastically 
reduced telomere length, which is sensed as DNA damage signal (Ozturk et al., 
2009). As a result of this DNA damage signal, key cell cycle regulators, such as p53, 
retinoblastoma protein, and p16INK4a are activated and cell cycle arrest occurs 
(Campisi, 2005).  
1.2.3 Senescence in liver 
Like other somatic cells, hepatocytes do not possess telomerase activity to 
compensate the telomeric loss at chromosome ends. Hence, during hepatocyte 
proliferation, shortening of telomeres is inevitable. Excess proliferation of 
hepatocytes results in progressive telomere shortening, eventually leading up to 
chronic liver diseases. Therefore, hepatocyte telomere shortening and resulting 
senescence phenotype are key features of liver cirrhosis (Wiemann et al., 2002). 
Cirrhosis is an important pathological factor for the development of HCC, and 
characterized by excessive collagen deposition. Collagen deposition in the liver 
causes the formation of nodules in the liver and acts as a key intermediate step for 
fibrosis (Farazi and DePinho, 2006).  
Senescence response is a pathological condition in the liver, but development of 
hepatocarcinogenesis requires further factors at this step. In fact, senescence of 
hepatocytes is a barrier for carcinogenesis through which cells require additional 
aberrations to pass this barrier, regain proliferative ability, and trigger HCC (Paradis 
et al., 2001). The main aberrations required to overcome the senescence barrier are 
inactivation of pRb and p53 pathways (Ozturk et al., 2009). The most common of 
these are the inactivation mutation of p53 gene and silencing of p16INK4a at the 
epigenetic level (Ozturk et al., 2009; Soussi, 2007).  
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1.2.4 Spontaneous replicative senescence 
Cancer cells have immortal characteristics. However, whether this characteristic is 
reversible or irreversible is still being questioned. In 2006, studies of Ozturk N. et al. 
showed that hepatocellular carcinoma cell line Huh7 derived cells can be 
reprogrammed into replicative senescence (Ozturk et al., 2006). In this study, Ozturk 
N. et al. made a long term culture of Huh7 cell line. After a long term culture, they 
obtained two sets of clones, namely C1/C3-Early/C3-Late and G11/G12-Early/G12-
Late. The C3 clone stopped proliferation at 80 population doublings (PD), while C1 
clone replicated over 150 PD. C3 clone was detected to be totally senescence-
associated β-galactosidase (SABG) positive, and BrdU negative. C1 clone and C3-
Early clones were similar. They showed normal Huh7 morphology, positive BrdU, 
and low percentage of SABG positive cells (Ozturk et al., 2006).  
On the other hand, Ozturk N. et al. showed that while immortal clone of Huh7 had 
hTERT activity, the spontaneous senescent C3 clone did not possess hTERT activity. 
Besides, SIP1 gene (ZFHX1B, Zinc finger homeobox 1B) expression was detected to 
be inversely correlated with hTERT expression in C3 senescent clones. In order to 
further show the effect of SIP1 on hTERT activity, shRNA targeting of SIP1 was 
done. Results indicated that knockdown of SIP1 released hTERT expression and 
rescued spontaneous senescent C3 cells from senescence arrest (Ozturk et al., 2006). 
This study was continued further in detailed with the expression profiling of the 
immortal and senescent Huh7 clones. Gene expression profiling was done using 
HU133Plus2 Affymetrix Chips and data was analyzed using R software. According 
to the results, the list of genes with statistically different expression between 
immortal and senescent clones involves 3073 genes. There is also a number of 
significant genes with differential expressions in other two-group comparisons, 2149 
genes between immortal (C1) and early senescent (C3-Early), and 2023 genes 
between early senescent (C3-Early) and senescent (C3) (Ozturk M. et al., 
unpublished data). 
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1.2.5 FAM134B as a senescence-associated gene  
Data analysis of gene expression profiling in senescent, pre-senescent and immortal 
clones of Huh7 resulted in detection of a number of differentially expressed genes in 
within three groups. Among these genes, there are some genes that have been and 
being studied extensively, while some are totally novel genes that were identified in 
whole genome sequencing but have not been studied and characterized yet. 
FAM134B (Family with sequence similarity 13, member B) was detected as a 
significant gene associated with senescence phenotype in this microarray study. 
FAM134B gene was represented with two different probes in the HU133Plus2 
Affymetrix chip. Probe codes are 218532_s_at and 218510_x_at. According to the 
probe 218532_s_at, FAM134B gene was detected to be 6.5 fold up-regulated in 
senescent clones in comparison to immortal clones, and 2.6 fold up-regulated in 
senescent clones compared to pre-senescent clones. On the other hand, microarray 
results according to other probe 218510_x_at, 4.9 fold up-regulation was detected in 
senescent clones with respect to immortal clones, while 2.8 fold up-regulation 
detected in senescent clones with respect to pre-senescent clones. Consequently, 
FAM134B was identified as one of the most significant genes showing differential 
expression between senescent and immortal clones with a p-value of 1.097 E-06 
(Ozturk M., unpublished data). According to these results, FAM134B is a senescence 
associated gene, and supposedly has a role in obtaining senescent phenotype or 
acquisition of senescence phenotype brings about increased expression of this gene. 
Therefore, the relationship between FAM134B gene and senescence is worth 
investigating in detail, especially because of the fact that it is a novel gene possibly 
having important functions in the cell context.               
1.3 Endoplasmic reticulum stress 
Endoplasmic reticulum (ER) is a key organelle in the cell functioning in the 
regulation and secretion of all proteins. After translation of linear proteins, these 
peptides enter into the ER and become mature in this organelle. The ER ensures 
proper folding and post-translational modifications of entered proteins before these 
proteins are transported to Golgi.  
11 
 
The lumen of ER is an environment with very high calcium ion concentration. 
Calcium ions are continuously transported into the ER by active transport through 
calcium ATPases. The lumen with high calcium ion concentration is a suitable 
environment for formation of disulfide bonds of proteins. Thanks to such oxidative 
environment and presence of calcium-dependent chaperone proteins in the ER, 
protein folding is done within the ER and folded proteins are transported out (Xu et 
al., 2005). 
ER works in a dynamic fashion. The flux into the ER is not always at the same level, 
changing according to the cells’ programs. Physiological state of the cell and 
environmental conditions are the main factors affecting the dynamic situation of the 
ER. ER always tries to keep protein mechanism well maintained. Therefore, protein 
folding capacity is adjusted in order to retain high fidelity. To maintain this 
homeostasis, ER requires sensors to determine the physiological conditions in the ER 
and signaling to regulate and maintain the homeostasis. However, homeostasis 
cannot be always well-maintained, resulting in an imbalance between the unfolded 
protein load in the ER and the effectiveness of ER machinery working on handling 
the situation. This imbalance is called endoplasmic reticulum stress (ER stress). The 
pathway reconciling the stress response and ER homeostasis is called unfolded 
protein response (UPR) (Ron and Walter, 2007). Presence of such a sensing 
mechanism and regulation was detected in a study showing that increasing the 
unfolded protein load of ER results in increased expression of ER lumen chaperones 
(Kozutsumi et al., 1988).  
1.3.1 Handling mechanisms for endoplasmic reticulum stress  
When an imbalance between accumulated unfolded proteins and the ER machinery 
occurs, the cell tries to overcome this situation by acquiring some adaptations. This 
intrinsic protection mechanism of cells is primarily focused on maintaining 
homeostasis at both cellular and tissue levels. Therefore, these adaptations may aim 
to relieve the stress or to remove the stressed cell from the tissue. 
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The first response against stressed ER is the reduction of unfolded protein load in the 
ER. This is a kind of transient solution for alleviating ER stress. The amount of 
accumulated unfolded proteins is reduced by some regulations, either aiming to 
decrease the amount of newly synthesized proteins or preventing entering of peptides 
into ER. Both of these regulations seek a solution for stressed ER by reducing the 
amount of proteins being processed in the ER. Secondly, apart from reducing the 
amount of proteins in the ER, cells acquire a further protection by increasing the 
working capacity of the ER machinery. This adaption is a long term response 
involving UPR target genes. Long term adaptation aims lessening ER stress by 
activating key UPR target genes encoding ER chaperone proteins. In this case, the 
more chaperones are produced and work in the ER, the faster ER stress is alleviated 
thanks to increased activity of these chaperones in proper folding of proteins. If both 
of these mechanisms do not result in alleviation of ER stress, cells activate a third 
mechanism, which is programmed cell death. This takes place in situations where ER 
homeostasis is no longer possible to be set up again. Hence, keeping homeostasis at 
organism level is preferred and stressed cell is programmed into controlled cell death 
(Ron and Walter, 2007).  
1.3.2 Components of unfolded protein response  
Unfolded protein response is the signal transduction response activated as a result of 
stress in the ER. So far, three different ER stress signal transducers have been 
identified in the ER. Each of these three initiates a signal transduction through a 
particular branch of UPR. These three elements are Inositol requiring protein 1 
(IRE1), activating transcription factor 6 (ATF6), and PKR-like ER kinase (PERK) 
(Ron and Walter, 2007).  
Inositol requiring protein 1 is the highly conserved arm of UPR. This element was 
firstly identified in yeast and found to be encoded by IRE1 gene. This gene encodes a 
ER transmembrane protein with a luminal and a cytoplasmic domain (Cox et al., 
1993). Cytoplasmic domain of IRE1 consists of a kinase activity, which is triggered 
by activation of ER stress signal coming from the luminal part. Following the 
activation signal, IRE1 activates itself by oligomerization and trans-
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autophosphorylation of the kinase domains (Credle et al., 2005; Zhou et al., 2006). 
Activation of the kinase domain of IRE1 also activates its other functional response, 
endonucleolytic cleavage. The substrate of this endonucleolytic activity is a 
transcription factor Hac1 in yeast (Cox and Walter, 1996; Mori et al., 1996), and X-
box binding protein 1 (XBP1) in metazoans (Calfon et al., 2002). IRE1 dependent 
transcriptional regulation works through its endonucleolytic activity to cleave and 
remove an intron from XBP1 mRNA. This cleavage makes XBP1 transcription 
factor active by leading spliced XBP1 mRNA to translation (Lee et al., 2002; 
Yoshida et al., 2001). Apart from activation of XBP1 by endonucleolytic cleavage, 
XBP1 expression is also controlled at the transcription level during UPR. XBP1 
mRNA levels are increased as UPR is induced (Yoshida et al., 2006). Functional 
XBP1 protein works as a transcription factor at the promoter sites of some genes 
having role in endoplasmic reticulum associated protein degradation and transport of 
unfolded proteins out of ER (Rao and Bredesen, 2004). Furthermore, with 
accompany of NF-Y, XBP1 binds to two different types of cis-acting elements, 
which are ER stress enhancer and UPR element (Yoshida et al., 2001). On the other 
hand, IRE1 is responsible for activation of kinases having role in inflammation and 
cell death machinery in association with TRAF2. Downstream of IRE1, TRAF2 
activates kinase Ask1 and stress induced Jun N-terminal kinase (JNK) (Urano et al., 
2000), as well as caspase-12 of apoptotic pathway (Yoneda et al., 2001).  
Other arm of the UPR signals through activating transcription factor 6. ATF6 was 
firstly identified as a new class of UPR signal transducer specifically in metazoans 
(Haze et al., 1999). ATF6 is found tethered to ER membrane as an inactive 
precursor. Upon activation of UPR, ATF6 is transported from ER membrane to 
Golgi apparatus. In Golgi, ATF6 undergoes two protease cleavages, which are 
processed by site 1 protease (S1P) and by site 2 protease (S2P), respectively. After 
cleavage, remaining active ATF6 fragment translocates into the nucleus to activate 
expression of target genes (Haze et al., 1999; Ye et al., 2000). ATF6 activates 
expression of a set of UPR genes including XBP1 (Yoshida et al., 2001). When UPR 
signal is activated, IRE1 and ATF6 arms of UPR act cooperatively in a way that 
while ATF6 increases the transcription of XBP1, IRE1 undertakes endonucleolytic 
cleavage and activating role of XBP1 to trigger expression of target alarm genes.  
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The third arm of UPR involves PKR-like ER kinase. PERK is activated similar to 
IRE1 by oligomerization of PERK and trans-autophosphorylation of its cytoplasmic 
domain (Bertolotti et al., 2000). In addition to its autophosphorlyation function, 
PERK also phosphorylates eukaryotic translation initiation factor-2-alpha (eIF2α) at 
Ser51 site. Ser51 phosphorylation of eIF2α results in inhibition of eIF2α re-cycling 
by guanine nucleotide exchange factor eIF2B. Lack of eIF2B functioning on eIF2α 
decreases the amount of active GTP-bound form of eIF2α. As a result of less active 
eIF2α, general translation initiation is halted, thereby reducing the amount of newly 
synthesized proteins (Harding et al., 1999). Activation of the PERK arm not only 
signals through reduction of translation, but also regulates activation of some 
downstream targets. For instance, activating transcription factor-4 (ATF4) and 
nuclear factor ĸB (NF-ĸB) are activated at translational and post-translational levels 
via PERK signaling (Ron and Walter, 2007). ATF4 activated another important 
transcription factor C/EBP homologous protein (CHOP). Signaling cascade 
continues with the targets of CHOP, which are growth arrest and DNA damage-
inducible protein-34 (GADD34) and ER oxidase-1 (ERO1) (Marciniak et al., 2004).                                   
1.3.3 Sensing the stress 
Activation of UPR is dependent on sensing stressed ER. Because ER is stressed due 
to the accumulation of unfolded proteins, heavy unfolded protein load must be 
sensed in order to start a signal transduction through three main arms of UPR. The 
most common chaperone protein BiP is the key sensor for ER stress (Rutkowski and 
Kaufman, 2004). One of the three main elements of UPR, ATF6, is held in the ER 
via protein-protein interaction with BiP (Shen et al., 2002). Other UPR element, 
IRE1 is also retained associated with BiP via its lumenal domain (Liu et al., 2003). 
And, the last arm of UPR, PERK, is also located on ER membrane and bound to BiP 
through hydrophobic regions on its lumenal domain (Ma et al., 2002).  
Sensing stress via BiP relies on the ability of BiP to bind peptide binding regions of 
proteins. BiP binds to both these three UPR elements and unfolded proteins thanks to 
this region. In the unstressed ER, the most abundant chaperone in the ER, BiP, binds 
to lumenal domains of PERK and IRE1, preventing dimerization of these UPR 
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elements to become active. In the stressed ER, due to excess unfolded proteins, BiP 
starts binding to unfolded proteins, decreasing its affinity to PERK, IRE1 and ATF6. 
Dissociation of BiP from PERK and IRE1 allows homodimerization and 
autophosphorylation of these proteins, which activates these two arms of UPR. On 
the other hand, dissociation of BiP from ATF6 releases ATF6 to transport into Golgi 
and become activated by proteolytic cleavage (Rutkowski and Kaufman, 2004). 
1.3.4 Deciding survival or death during ER stress  
Accumulation of excess unfolded proteins in the ER triggers UPR to somehow 
overcome this unfavorable situation. Three main elements of UPR control activities 
of some key regulators functioning in the cell death response. While the decision of 
cells’ survival or death relies on the activities of these key UPR elements, actual 
factor behind this scenario is dependent on how severe the cell experiences a stress in 
the ER and how persistent the stress is. 
ER associated cell death is likely to be controlled by the level of calcium ions in the 
ER. Calcium ions might take a role in activation of proteases in cytoplasm to induce 
cell death (Nakagawa and Yuan, 2000). However, there is no detected relationship 
between the ER stress and release of calcium from the ER so far. ER stress might 
contribute to apoptosis through some key apoptotic regulator, such as BAX and 
BAK. These death factors normally reside in the ER, but translocating onto 
mitochondria membrane, where they can function upon ER stress (Scorrano et al., 
2003; Wei et al., 2001). ER stress mediated cell death might also signal through 
IRE1 branch of UPR. In this case, caspase-12 activation with the help of TRAF2 
triggers death in mice (Nakagawa et al., 2000). Paralog of mice caspase-12 in human, 
caspase-4 is also associated with the ER functioning, possibly performing a similar 
role of its paralog in mice (Hitomi et al., 2004). Furthermore, IRE1 mediated Ask1 
activation leads to JNK activation, resulting in the phosphorylation of JNK targets. 
Among these targets, phosphorylation of Bcl-2 inhibits its anti-apoptotic activity 
(Yamamoto et al., 1999), whereas phosphorylation of Bim results in activation of its 
pro-apoptotic function (Lei and Davis, 2003). At the transcription factor level, ER 
stress induced apoptosis is regulated by CHOP (GADD153). CHOP can repress the 
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expression of anti-apoptotic Bcl-2, resulting in the promotion of cell death 
(McCullough et al., 2001). In brief, at least two of the three branches of UPR have 
already been detected as factors in ER stress induced cell death. Therefore, cell death 
response is likely to be resulted from the cooperative role of different UPR signaling 
elements. Even though the primary goal of UPR is to alleviate the stress level in the 
ER, if the improper folding process in the ER is excessive or persistent, UPR 
response aims directing cells to death, typically apoptosis (Xu et al., 2005).                                      
1.4 Liver and ER stress 
The major cell type in the liver, hepatocytes, is a type of cell specialized in metabolic 
activities. Hepatocytes are responsible for high amount of protein synthesis and 
secretion in the body. Since the endoplasmic reticulum is the site where post 
translation control of synthesized proteins is done, ER in hepatocytes has to work at 
maximum capacity. Under normal circumstances, hepatocytes can handle this 
massive work of protein synthesis, folding and port-translational modification, and 
secretion in a routine way thanks to presence of abundant endoplasmic reticulum. 
However, hepatocyte ER might be stressed upon emergence of some internal and 
external factors. Viral infections to hepatocytes, alcohol and drug usage, metabolic 
disorders, and mutations in ER protein encoding genes are the main causes of 
stressed ER in the liver (Ji and Kaplowitz, 2006). 
Stressed ER in hepatocytes can be overcome by common adaptive stress response, 
UPR. When ER stress is induced by the abovementioned factors, UPR is activated 
and tries to overcome the stress by inducing ER resident proteins having role in 
protein folding, triggering degradation of unfolded proteins, and decreasing the total 
protein synthesis in ribosomes. In a case that ER stress cannot be assuaged by these 
adaptations, continual stress brings about pathological outcomes in the liver. 
Hepatocyte death, inflammation and accumulation of hepatic fat are among these 
pathological consequences or uncontrolled ER stress. These conditions may lead to 
liver diseases and contribute to the occurrence of liver injury and exacerbate the 
prevailing liver disease of other aetiological factors, such as viral infection or 
diabetes associated liver disease (Ji and Kaplowitz, 2006).           
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1.5 FAM134B in the literature  
Family with sequence similarity 134, member B (FAM134B) is a novel gene 
belonging to the same family with FAM134A and FAM134C. Even though there is a 
few publications related to this gene, its function is still not known. All the 
information that has been identified so far is summarized below. 
In 2007, the studies of Tang et al. were published in an article titled ‘Oncogenic 
properties of a novel gene JK-1 located in chromosome 5p and its overexpression in 
human esophageal squamous cell carcinoma.’ This research showed that novel gene 
JK-1, which is the name of FAM134B isoform number 2, is associated with 
esophageal squamous cell carcinoma (ESCC) and has a transforming capacity in 
normal cells. Firstly, their results indicated that JK-1 is overexpressed in 69% (9/13) 
of ESCC cell lines and 30% (9/30) of ESCC patient samples. Furthermore, when 
they overexpressed JK-1 in normal cell types, NIH3T3 and HEK293, these cells 
possessed anchorage dependent and anchorage independent growth. And also, Tang 
et al. reported that subcutaneous injection of JK-1 overexpressing NIH3T3 cells 
created subcutaneous sarcomas in all (3/3) three mice. In brief, this study provided 
the first evidence for JK-1’s transforming capacity and JK-1 may be associated with 
the pathogenesis of ESCC (Tang et al., 2007). 
In 2009, Kurth et al. published an important article, titled ‘Mutations in FAM134B, 
encoding a newly identified Golgi protein, cause severe sensory and autonomic 
neuropathy’, indicating the first evidence that FAM134B mutation is associated with 
a neurodegenerative disease. In their study, genome-wide homozyosity mapping in 
the sample family having hereditary sensory and autonomic neuropathy type II 
(HSANII) disease resulted in focusing on a candidate region of 5p15.1. Further 
analysis pointed out a homozygous nonsense mutation in the FAM134B gene. In 
order to detect the specific tissues expressing this gene, they performed an in situ 
hybridization assay. The results showed that FAM134B is predominantly expressed 
in sensory and autonomic ganglia, while other family members FAM134A and 
FAM134C are strongly expressed in central nervous system as wells as organs like 
liver, lung and kidney. Their localization studies resulted in the detection of 
FAM134B protein co-localized with cis-Golgi marker giantin in N2a cells, 
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autonomic ganglion neurons related tumor cell line. In order to test the role of 
FAM134B in the structure of Golgi, they knocked down FAM134B with a lentiviral 
approach in N2a cells. Knock down of FAM13B4 resulted in a significant reduction 
in the cis-Golgi size, with a reduction rate of 38% and 40% for two different RNAi. 
On the other hand, they noticed induction of apoptosis in cultured dorsal root ganglia 
(DRG) neurons when they are infected with lentiviral approach to knock down 
FAM134B. However, unlike DRG neurons, when mouse hippocampal pyramidal 
neurons were infected with the same RNAi approach, these cells were not affected. 
This might point out that nociception neurons are specifically sensitive to FAM134B 
depletion. In brief, this study indicated that FAM13B4 has an important role in 
survival of sensory and autonomic ganglia neurons. Because other members of the 
same family, family with sequence similarity 134, were also detected to be 
predominantly expressed in the nervous system, it is likely to state that this family of 
proteins might have a general role in the maintenance of neurons (Kurth et al., 2009).  
Previous studies in our group detected FAM134B as a spontaneous replicative 
senescence-associated gene (Ozturk et al., unpublished data). Therefore, our group 
aimed to find out the relationship between FAM134B and senescence. To do that, 
firstly, its association with senescence, which was previously detected in the 
microarray study, was tested with semi-quantitative RT-PCR. Results showed that 
FAM134B is indeed over expressed in C3 senescent clone of Huh7 cells in 
comparison with parental Huh7 and C1 immortal Huh7 clone. Furthermore, 
localization immunofluorescence studies resulted in the detection of FAM134B 
colocalization with endoplasmic reticulum protein calnexin. On the other hand, 
because Huh7 HCC cells have low level of FAM134B, FAM134B overexpressing 
stable Huh7 cells were created. FAM134B is associated with replicative senescence. 
However, it was not known whether this is the cause or the result of senescence. To 
test this, senescence-associated β-galactosidase experiments were performed. Results 
showed that FAM134B overexpression does not induce senescence in Huh7 cells. 
Besides, further BrdU incorporation studies indicated that FAM134B does not induce 
or repress Huh7 cell proliferation (Tasdemir et al, unpublished data).  
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Studies on FAM134B so far come up briefly with the following information: its 
possible relationship with ESCC, its role in survival of specific neurons and 
neurodegenerative disease, its localization to endoplasmic reticulum or cis-Golgi, 
and its structural function in cis-Golgi. However, we still do not know much about 
the function of this protein in the contexts of general cell biology and hepatocellular 
carcinoma.                     
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2. OBJECTIVES AND RATIONALE 
Being one of the most common and lethal cancer types in the human population 
worldwide, hepatocellular carcinoma is a significant cancer type that awaits a cure. 
However, the molecular pathogenesis of hepatocellular carcinoma is a rather 
complex mechanism  (Farazi and DePinho, 2006). Indeed, through the progress of 
HCC, different risk factors and modulations, such as mutation, altered pathways, 
genetic changes, epigenetic changes, and chromosomal aberrations are involved 
(Bruix and Sherman, 2005).  
Studies of Ozturk et al. showed that immortal HCC cell line Huh7 can be 
reprogrammed into replicative senescence, resulting in the loss of tumorigenic 
capacity of parental immortal cells (Ozturk et al., 2006). Acquisition of such a non-
proliferative capacity of immortal cells came up with the idea that directing immortal 
cells into senescence might be a potential therapeutic approach to tumorigenesis. 
Designing promising therapies relies on the characterization of the features of 
immortal and replicative senescent cells in detail. As being one of the most 
significantly upregulated gene in senescent clones, FAM134B might undertake a 
critical function in the context of HCC.  
On the other hand, Studies of Kurth et al. indicated that mutation in FAM134B is 
associated with HSANII neurodegenerative disease. Knock down of FAM134B in 
neural cells results in decreased cis-Golgi size, and induction of apoptosis in some 
neurons (Kurth et al., 2009). Therefore, FAM134B gene might have a significant role 
in the survival of neurons. Because senescence is also a survival but non-proliferative 
response, increased FAM134B expression in senescent cells is also correlated with 
its survival function in neuron.  
Lastly, FAM134B seems to have a structural function in the cis-Golgi and/or ER. 
Apart from its structural function, it might possess other critical functions related to 
the survival of the cells, cellular homeostasis and pathogenesis of diseases.    
21 
 
3. MATERIALS AND METHODS 
 
3.1 MATERIALS 
3.1.1 General Laboratory Reagents  
The reagents used in this research were bought from major biochemical companies 
such as Sigma-Aldrich (St. Louis, MO, USA) and Merck (Darmstadt, Germany). X-
gal was purchased from MBI Fermentas GmbH (Germany). Ethanol, methanol, 
haematoxylene and Bradford reagents were from Sigma-Aldrich (St. Louis, MO, 
USA). DMSO and Ponceau S were purchased from Applied Biochemia (Darmstadt, 
Germany). Plasmid maxi-prep kit used for plasmid extraction was purchased from 
Quiagen (Chatsworth, CA, USA). Nucleospin RNA II total RNA isolation kit was 
from Macherey-Nagel (Duren, Germany). Agarose was purchased from Sigma 
Biosciences (St. Louis, MO, USA). ECL+ blot detection kit and western blot 
membranes were purchased from Amersham Pharmacia Biotech Company. Yeast 
extract, agar and tryptone were from Gibco (Carlsbad, CA, USA) and BRL Life 
Technology Inc. (Gaithersburgs, MD, USA). TGF-β1 was purchased from R&D 
Systems (Minneapolis, USA).  
3.1.2 Tissue culture materials and reagents  
All plastic materials used in cell culture, such as petri dishes, plates, flask were 
purchased from Corning Life Sciences Inc. (USA). Dulbecco’s modified Eagle’s 
medium (DMEM) and Roswell Park Memorial Institute (RPMI) cell culture 
mediums were bought from GIBCO (Invitrogen, Carlsbad, CA, USA). Optimem 
transfection medium and lipofectamine 2000 transfection reagents were from GIBCO 
and Invitrogen, respectively. Furthermore, other cell culture reagents such as trypsin 
22 
 
EDTA, fetal bovise serum (FCS), penicillin/strepromycin antibiotics, and L-
glutamine were also purchased from GIBCO. 
3.1.3 Bacterial Strains 
The bacteria strain used in this research was E. coli DH5α strain. 
3.1.4 cDNA synthesis 
Fermentas RevertAid First strand cDNA synthesis kit (MBI Fermentas, Germany) 
was used for preparation of cDNAs for expression analysis.  
3.1.5 Polymerase chain reaction 
Semi quantitative polymerase chain reaction (PCR) reagents, 10X Taq DNA 
polymerase Buffer (+(NH4)2SO4 – MgCl2), Taq DNA polymerase, 2 mM dNTPs, 
25 mM MgCl2 were bought from MBI Fermentas. Quantitative RT-PCR reaction 
reagents DyNAmo HS SYBR Green qPCR Kit F-410 was purchased from 
Finnzymes.  
3.1.6 Nucleic acids 
DNA molecular weight markers were purchased from MBI Fermentas (Germany). 
pCMV10-FLAG and pCMV14-FLAG plasmids were from Sigma-Aldrich (St.Louis, 
MO, USA). pGIPZ and pGIPZ-shFAM134B plasmids were purchased from Open 
Biosystems. 
3.1.7 Oligonucleotides 
Primer Sequence Tm 
hFAM134B isoform 1 For. CAAGAGGTGCACAGTTGTGGAGAA 58 
hFAM134B isoform 1 Rev. GCAACCGTGAGGCTAATCTTAGGA 58 
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hFAM134B isoform 2 For. CTCGAGAAGCTTATGCCTGAAGGTGAAGACTT 58 
hFAM134B isoform 2 Rev. GCAACCGTGAGGCTAATCTTAGGA 58 
hXBP-1 For.  TTACGAGAGAAAACTCATGGCC 58 
hXBP-1 Rev.  GGGTCCAAGTTGTCCAGAATGC 62 
hGAPDH For.  GGCTGAGAACGGGAAGCTTGTCAT 60 
hGAPDH Rev.  CAGCCTTCTCCATGGTGGTGAAGA 60 
hVimentin For. CGTCACCTTCGTGAATACCA 60 
hVimentin Rev. CCAGAGGGAGTGAATCCAGA 60 
hFAM134B isoform 1 For. TTGGGCGTGTTATTATGCAA 53 
hFAM134B isoform 1 Rev. GCCAGGGCTCTGCTGTTTA 58 
hFAM134B isoform 2 For. CACATTAGCCGTGGTTAGCA 57 
hFAM134B isoform 2 Rev. TTCTGCAATACAGTGGCTGAG 58 
hFAM134B common  For. TGGGACCTTCAACCTTTCAG 57 
hFAM134B common  Rev. ATTGCGTCTCTTTGCTTGGT 55 
Table 3.1 : Primer list, sequences and Tm values 
3.1.8 Electrophoresis, photography and spectrophotometry 
Agarose used for gel electrophoresis was purchased from Sigma Biosciences 
Chemical Company (St. Louis, MO, USA). Electrophoresis apparatus was from 
Thermo Electron Corporation. Power supplies PAC-200 and PAC-300 were bought 
from Bio Rad Laboratories (CA, USA). Nucleic acid concentration were measured 
by using NanoDrop from Thermo Scientific (Wilmington, USA). Bradford based 
protein concentration measurements were done using spectrophotometer Beckman 
Du640 from Beckman Instruments Inc. (CA, USA).  
3.1.9 Antibodies 
Antibodies used in this study, their catalog numbers, and working dilutions are given 
below.  
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Antibody Company and catalog 
number 
Dilution 
FAM134B Sigma, HPA026906 1:2500 
FAM134B Sigma, AV44827 1:1000 
Calnexin Sigma, C4731 1:5000 
α-tubulin Calbiochem, CP06 1:4000 
Phospho-eIF2α Invitrogen, 44728G   1:1000 
Phospho-PERK Cell Signaling, 3179 1:1000 
Phospho-Rb Cell Signaling, 9398 1:1000 
BrdU DAKO, M0744 1:500 
Anti-mouse-HRP Sigma, A0168 1:5000 
Anti-rabbit-HRP Sigma, 6154 1:5000 
Anti-mouse/rabbit-Alexa 
Fluor 488 
Invitrogen, A11034 1:750 
Flag M2 Sigma, F1804 1:5000 
PARP Santa Cruz, sc8007 1:250 
Cleaved caspase 3(Asp 175) Cell signaling, 9664 1:500 
Vimentin Dako, M7020 1:500 
Table 3.2: Antibody list, catalog numbers and working dilutions  
25 
 
3.2 SOLUTIONS AND MEDIA 
3.2.1 General solutions  
50X Tris Acetate EDTA (TAE) 242 g Tris base, 57.1 ml glacial acetic acid, 
18.6 EDTA were dissolved in 1 liter ddH20 
Working dilution is 1X  
10X Phosphate Buffered Saline (PBS) 80 g NaCL, 2 g KCl, 14.4 g Na2HPO4, 2.4 
g KH2PO4 in 1 litre ddH2O 
Working dilution is 1X 
Ethidium bromide  10 mg/ml dissolved in ddH2O (stock) 
Working concentration is 30 µg/ml 
 
3.2.2 Bacteria solutions  
Luria-Bertani medium (LB medium) 10g bacto-tryptone, 5 g bacto-yeast extract 
and 10g NaCl for 1 litre. Additionally, 15 
g/L bacto agar for LB agar plates 
Glycerol stock solution Final concentration of glycerol is 25% in LB  
Ampicillin  100 mg/ml stock solution in ddH2O 
Working solution is 100 µg/ml 
3.2.3 Tissue culture solutions  
DMEM/RPMI media  Complete medium contains 10% Fetal 
bovine serum, 1% penicillin/streptomycin, 
1% non-essential amino acids, stored at 4 ̊C  
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10X Phosphate buffered saline (PBS) 80 g NaCL, 2 g KCl, 14.4 g Na2HPO4, 2.4 
g KH2PO4 in 1 litre ddH2O 
Working dilution is 1X, stored at 4 ̊C 
 
3.2.4 Senescence associated β-galactosidase (SABG) solutions 
SABG solution 1 mg/ml X-gal, 2 mM MgCl2, 150 mM 
NaCl, 5 mM potassium ferricyanide, 5 mM 
potassium ferrocyanide, 40 mM citric acid/ 
sodium phosphate buffer (pH 6) 
3.2.5 BrdU incorporation assay solutions  
BrdU 10 mg/ml BrdU in ddH2O stock 
Working dilution is 30 µM 
2N HCl  8.62 ml of 37% HCl, 16.36 ml H2O 
PBS-TritonX 100  0.1% TritonX-100 in PBS  
3.2.6 Immunofluorescence assay solutions  
Immunofluorescence blocking solution 10% FCS in 0.2% PBS-Tween 20 
Washing solution 0.2% PBS-Tween 20 
Antibody dissolved in  2% FCS in 0.2% PBS-Tween 20 
DAPI (4’,6-diamino-2-phenylindole) 0.1-1 µg/ml working solution in PBS or 
ddH2O 
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3.2.7 Propidum iodide cell cyle analysis solution 
Propiduim iodide solution 50 µg/ml propidium iodide, 0.1 mg/ml 
RNase A and 0.05% TritonX-100 in PBS 
 
3.2.8 Sodium Deodecyl Sulphate (SDS) – Polyacrylamide Gel Electrophoresis 
(PAGE) and immunoblotting solution  
In this study, NuPAGE NOVEX pre-cast western blotting system (Invitrogen, CA, 
USA) was used for the immunoblotting experiments. Pre-cast gels used were 4-12% 
gradient, 10% and 12% Bis-Tris gels. Furthermore, for the detection of high weight 
proteins 3-8% Tris-acetate pre-cast gels were used, all from Invitrogen. Running 
buffers were also purchased from Invitrogen. MES and MOPS ready to use 20X 
stock running buffers used according to the weight of the protein of interest. Wet 
transfers were done to either PVDF membrane or nitrocellulose. 20X transfer buffer 
for wet transfer, 4X sample loading buffer, antioxidant and 10X denaturing reagent 
(500 mM DTT) were also purchased from Invitrogen.   
Running buffers MES and MOPS 20X stock, working solution is 1X  
Transfer buffer (Invitrogen) 20X stock, working solution is 1X with 10% 
methanol 
Blocking solution 5% (w/v) non-fat dry milk was dissolved in 
0.2% TBS-Tween 20, or 2.5% Quick 
Blocker (Calbiochem) was dissolved in 
0.2% TBS-Tween 20 
10X Tris buffered saline (TBS) 12.9 g Trisma base, 87.76 g NaCl in 1 litre 
of ddH2O, working dilution is 1X and pH 8 
TBS-Tween 20 0.2% Tween 20 in 1X TBS 
Ponceau S  0.1% (w/v) Ponceau S and 5% (v/v) acetic 
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acid was dissolved in 0.2 % TBS-Tween 20 
Coomassie brilliant blue solution 100 mg coomassie brilliant blue G-250, 50 
ml 95% ethanol, 100 ml 85% phosphoric 
acid. Filtered using whatman paper 
NP-40 lysis buffer 50 mM Tris HCl, 150 mM NaCl, 1% NP-40, 
0.1% SDS, 1X protease inhibitor cocktail  
3.3 METHODS 
3.3.1 Tissue culture methods 
3.3.1.1 Cell lines and growth conditions of cells 
Hepatocellular carcinoma cell lines used in this study were cultured in either DMEM 
or RPMI media. Well-differentiated cell lines Huh-7, Hep40, HepG2, Hep3B, 
Hep3B-TR, PLC and also Mahlavu, Focus, SK-HEP-1 cell lines were cultured in 
complete DMEM medium. Other HCC cell lines Snu-182, Snu-387, Snu-398, Snu-
423, Snu-449, and Snu-475 were cultured in complete RPMI medium. 
DMEM and RPMI mediums used for culturing cells were complete mediums 
containing 10% fetal bovine serum, 1% penicillin/streptomycin antibiotics and 1% 
non-essential amino acids. All the cells were kept in incubators at 37 °C with 5% 
carbon dioxide concentration in the air. All the cells kept in incubators were checked 
regularly. Cells were passaged into new dishes or plates before they reached high 
confluency in the dish.  
3.3.1.2 Passaging the cells 
For passaging cells, firstly, the medium was aspirated using sterile pipettes and the 
cells were washed at least once with PBS. Thereafter, trypsin-EDTA was added in 
the dish or flask. The amount of trypsin-EDTA was between 0,5 ml- 2ml, depending 
on the surface area of the dish or plate. Trypsinized cells were kept in the incubator 
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for 1-2 minutes. Then, detached cells were collected in a complete medium in 15 or 
50 ml falcon tubes, using serological pipettes. Cells were mixed by pipetting up and 
down. Desired portion of the collected cells were reseeded on petri dishes or flasks 
depending on the requirements.  
3.3.1.3 Thawing the cells  
For thawing the cells, stock cryovial of a cell line of interest was taken from either 
from nitrogen tank stocks or from – 80 °C freezer stocks and put on ice immediately. 
Thereafter, the vial was put in the 37 C water bath in order to thaw in a few minutes. 
Before thawing completely, cells were pipetted using a several milliliters of 
completes medium and transferred into 15 ml tubes. Resuspended cells were 
centrifuges for 4 minutes at 1500 rpm. Supernatant containing DMSO was removed 
and cell pellet was resuspended in a complete medium and transferred into petri dish 
or flask. Flasks and dishes were chosen depending on the amount of pellet, smaller 
flask or dish for less amount of cell pellet. Cells were distributed in the flask or dish 
evenly by moving the flask or the dish back-forth and right-left. Cells were kept in 
incubators, at 37 C and 5% carbon dioxide conditions. The day after, cells were 
washed and unattached cells were removed and the mediums were refreshed.  
3.3.1.4 Cryopreservation of the cells  
Cell stocks were prepared from the cell in culture with around 60-70% confluency. 
These cells were washed with PBS and collected by adding trypsin-EDTA and 
medium afterwards. Cells were centrifuged for 4 minutes at 1500 rpm. Thereafter, 
freezing medium, containing 7% DMSO and 20% FSB in complete medium, was 
used for resuspending the cells. Cells in freezing medium were transferred into 
cryotubes and kept at -20 °C for about 1 hour. Afterwards, cryovials were stored at – 
80 °C overnight and transferred into nitrogen tanks.  
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3.3.1.5 Transient transfection of cells using Lipofectamine 2000  
Transfection of plasmid DNA into cells was done by using Lipofectamine 2000 
transfection reagent (Invitrogen, CA, USA). Firstly, cells were seeded in 6 well or 12 
well plates one day before the transfection. Transfection was done when cells have 
high confluency. OPTI-MEM and Lipofectamine 2000 mixture and OPTI-MEM and 
DNA mixtures were prepared. Thereafter, these mixtures were mixed and let to stay 
at room temperature for 30 minutes. Thereafter, cells were washed with PBS and 
transfection mixture was added on cells. After 6-8 hours, Lipofectamine containing 
transfection mixture was removed, cells were washed and fresh growth medium was 
added on cells. For determining transfection efficiency, a control GFP vector was 
also transfected into control cells and efficiency was checked under fluorescent 
inverted microscope. Cells were collected about 48h after transfection for western 
blot experiment. In this protocol, DNA:Lipofectamine 2000 ratio was 1:2,5. The 
transfection medium used was OPTI-MEM serum medium from GIBCO.  
3.3.1.6 Treatment of the cells  
Firstly, cells were seeded in appropriate dishes, flasks or plates according to the 
experiment type. One day after the seeding, the mediums were removed. Cells were 
washed with PBS. Treatments were done in complete DMEM or RPMI mediums. 
Treatment mediums containing chemicals, such as thapsigargin, tunicamycin etc. 
were prepared freshly. For the control samples, complete mediums containing same 
amount of solvents were prepared, such as water or DMSO.   
3.3.2 Total RNA extraction from cultured cells 
For RNA extraction from the cultured cells, first of all, cells were collected by 
adding trypsin-EDTA and growth medium. Then, cells were centrifuged and the 
pellets were used for RNA extraction using NucleoSpin RNA II Kit (MN Macherey-
Nagel, Duren, Germany) according to the manufacturer’s protocol.  
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3.3.3 First strand cDNA synthesis 
First strand cDNAs were synthesized by using Fermentas RevertAid cDNA synthesis 
Kit (MBI Fermentas, Germany). 1-2 ug RNA was used for cDNA synthesis 
according to the manufacturer’s instruction. Firstly, Oligo(dT)18 primers were added 
into RNA and this provided reverse transcription of only mRNAs with polyA tails. 
After addition of reaction buffer and dNTPs, RevertAid M-MuLV RT reverse 
transcriptase enzyme did the reverse transcription at 42 °C. All these steps with 
different temperatures were done in thermocycler machine. Total final volume of 20 
cDNA was diluted to 1:1 in DEPC-treated water. 
3.3.4 Primer designing for semi-quantitaive and real time RT-PCR analysis   
In order to obtain efficient results from expression analysis, primers for semi-
quantitative and quantitative RT-PCR were designed carefully. Designed forward 
and reverse primers were arranged in a way that they anneal on different exons. 
Thereby, amplification from the genomic DNA was not expected. Even if so, primers 
were designed in a way that amplification from genomic DNA would give a greater 
product which could be detected on the gel. Furthermore, primers were designed in a 
way that they contain low GC content, especially at the ends of the primers and also 
forward and reverse primers have approximately the same melting temperatures.  
3.3.5 Detection of genomic DNA contamination in cDNA synthesis 
For the detection of any unexpected amplification from genomic DNA cDNA 
synthesis was done using a reverse transcriptase control samples. In this control 
experiment, all the RNA samples were prepared exactly the same according to the 
cDNA synthesis kit protocol except the addition of RevertAid reverse transcriptase 
enzyme. In lack of this enzyme, cDNAs were not expected to be synthesized. 
Therefore, if the PCR gives a product, this was expected to be amplified from 
genomic DNA. When each cDNA set was prepared, these RT – control samples were 
checked at least once by RT-PCR and run on the agarose gel. On the other hand, 
control PCR was done using glyceraldehyde-3-phosphate dehydrogenase primers in a 
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way that these primers were designed to give a product of 151 bp from cDNA but 
250 bp product from genomic DNA.  
3.3.6 Expression analysis of a gene by semi-quantitative RT-PCR 
3.3.6.1 GAPDH normalization  
When a cDNA set was synthesized, first of all GAPDH RT-PCR was done in order 
to normalize the amounts of cDNAs to use in PCR reactions. GAPDH RT-PCR was 
run on the agarose gel to detect the band intensities. According to the band intensities 
GAPDH normalization was done aiming to equalize the GAPDH intensity, thereby, 
providing an efficient comparison of the expression of the gene of interest in the 
samples. After relative GAPDH PCR product intensities were detected on the gel, the 
amount of cDNAs for the next RT-PCR were estimated and the other RT-PCRs were 
done using these amounts of cDNAs from the same cDNA samples.  
3.3.6.2 Choosing optimum cycle for RT-PCR 
Optimum cycles for a particular RT-PCR analysis may vary according to the gene of 
interest, primer efficiency and cell line of the sample. Therefore, for each set of 
primers and cell line combinations, optimum cycle numbers were aimed to be 
detected. To do this, different cycle numbers were tested on run on the gel. The 
optimum cycle number in which bands can be seen clearly but the product amounts 
are not so high that the differences between the band intensities cannot be noticed, 
was chosen as an optimum cycle and the following PCR reactions were done with 
this cycle number.  
3.3.7 Agarose gel electrophoresis 
DNA samples and PCR products were detected on agarose gel using horizontal gel 
electrophoresis. Gels were prepared and run in 1X TAE buffers with different 
agarose concentrations between 1-3% depending on the size of the DNA fragment. 
Smaller DNA fragments were run on 2% agarose gels, while larger ones were run on 
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1% agarose gels. RT-PCR products of XBP-1 gene were run on 3% agarose gels 
because of the reason that the transcript variant 1 and variant 2 of the XBP-1 gene 
has only 26 base difference in length. It was possible to detect the change between 
unspliced and 26 bases shorter spliced form of this gene on 3% agarose gel. During 
preparation of the gel, corresponding amount of agarose was dissolved in 1X TAE 
buffer and boiled in microwave. Then, the solution was left to cool down for a while 
and ethidium bromide was added on with a final concentration of 30 µg/ml before 
pouring the gel. DNA samples were mixed with 6X bromophenol blue or xylene 
cyanol loading dyes before loading into the gel. Agarose gels were run at room 
temperature under around 100-120 V voltage. 100 bp or 1 kb ladders were used as a 
reference point on the gels when the gels were visualized under UV light.        
3.3.8 Expression analysis of a gene by quantitative RT-PCR    
Quantitative PCR analysis was done using Stratagene Mx 3005P. DyNAmo HS 
SYBR Green qPCR Kit F-410 from Finnzymes was used for the quantitative RT-
PCR experiments, according to the manufacturer’s protocol. Real time PCR reactions 
were prepared in 20 µl total volume containing 1 µl cDNA sample. Reactions started 
with initial denaturation step at 95 °C for 10 minutes. Then, 40-45 cycles of 
amplification reaction was performed at 95 °C 30 seconds, at 58-60 °C  30 seconds, 
at 72 °C 30 seconds. Expression levels of the genes were calculated according to the 
Ct value of the amplification of the gene of interest, Ct value of the reference gene 
(GAPDH) and efficiency of the primer used. Efficiencies of the primers were 
calculated before the actually expression analysis by making a serial dilution of a 
cDNA pool. All real time RT-PCR experiments were performed in at least duplicates 
of each sample.  
3.3.9 Bromodeoxyuridine (BrdU) assay 
In order to detect the ratio of proliferating cells, cells were incubated with 30 µM 
bromodeoxyuridine for 2 hours after particular treatments. Thereafter, cells were 
fixed with ice-cold 70% ethanol for 10 minutes. Then, cells were exposed to 2 N HCl 
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for 20 minutes to denature their DNA. Incorporated BrdU was detected using anti-
BrdU monoclonal antibody (1:500 dilution) for 1 hour. As a secondary antibody, 
Alexa Flour 488 anti-mouse (1:750 dilution) was used and cells were counter stained 
with DAPI (1/10000 in water) for 1 minute. Then, cover slips were covered on slides 
using fluorescence mounting medium and observed under fluorescence microscope.     
3.3.10 Cell cycle analysis using flow cytometry 
In order to test the cell cycle distribution of the cells after treatment, cells were rinsed 
with 1X PBS and trypsinized. Then, cells were collected by centrifugation and 
resuspended in 1ml of 1X PBS. Cells in PBS solution was fixed by adding 2,5 ml 
absolute ethanol for 15 minutes or kept at 4 °C in ethanol if the experiment continued 
later on. After fixation of the cells, cells were pelleted again and propidium iodide 
solution (50 µl/ml propidium iodide, 0.1 mg/ml RNase A, and 0.05 % TritonX-100) 
was added to resuspend the pellet. Cells were incubated with this solution for 45 
minutes at 37 °C. Then, cells were centrifuged to remove PI solution at 1500 rpm for 
4 minutes and were transfer into polystyrene tubes by resuspending with 
corresponding amount of PBS depending on the pellet size. Analysis was done using 
FACSCalibur Flow Cytometer (BD Biosciences) and the results were analyzed and 
figured using Cell Quest 3.2 software.      
3.3.11 Senescence associated β-galactosidase (SA-β-Gal) assay 
SA-β-Gal assay was performed by seeding cells on circular or square cover slips put 
in 6-well or 12-well plates. After treatments are finished, cells were washed with 1X 
PBS and fixed with 4% formaldehyde for 10 minutes at room temperature. Then, 
SA-β-Gal buffer was added on the cells and the plates were covered with aluminum 
foil. Plates were kept at 37 °C in a CO2-free incubator for 12-16 hours or until the 
blue-green staining was detected in the cells.   
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3.3.12 Immunofluorescence staining assay 
For immunofluorescence staining, first of all, cells were fixed with 4% formaldehyde 
for 10 minutes at room temperature. After fixation, cell permeabilization was done 
using 0.5% saponin, 0.3% TritonX-100 in 1X PBS solution for 10 minutes at room 
temperature. Permeabilized cells were blocked with 10% fetal calf serum (FCS), and 
0.1 TritonX-100 in 1X PBS for 1 hour at room temperature. After blocking, primary 
antibody incubation was done using a specific antibody prepared in 2% fetal calf 
serum and 0,1% TritonX-100 in 1X PBS for 1 hour at room temperature. Primary 
antibodies were removed and cells were washed with PBS-TritonX-100. Then, 
secondary fluorescent antibodies, anti-rabbit or anti-mouse Alexa Fluor 488 were 
used for the detection of the primary antibody. After secondary antibody incubation, 
cells were counter stained with DAPI (1:10000 dilution in ddH2O) for 1 minute. 
Finally, cover slips were mounted on slides using fluorescent mounting medium and 
visualized and photographed under fluorescence microscope.  
3.3.13 Total protein extraction from cultured cells 
Cells in flasks of dishes were collected either by trypsinization or by scraping. Then, 
appropriate and sufficient amount of lysis buffer (RIPA buffer in general) was added 
on the cell pellet and cells were mixed with the lysis buffer properly by pipetting up 
and down and vortexing every 5 minutes for 30 minutes. Thereafter, lyzed cells were 
centrifuged at 11000 g for 30 minutes and the supernatants were collected in pre-
chilled new eppendorf tubes. Protein concentrations were measured using Bradford 
reagent. Already known BSA measurements were used as a reference. All the 
measurements were done with spectrophotometer.  
3.3.14 Total protein extraction from tissues 
Mouse (Mus musculus) and rat (Rattus norvegicus) organs were taken from Animal 
Facility in the Department of Molecular Biology and Genetics at Bilkent University. 
Organs were immediately frozen in liquid nitrogen and stored at -80 °C freezers. 50-
100 mg of each tissue were homogenized with pestle and mortar in liquid nitrogen. 
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Then, powders of the tissues were transferred into glass tubes in an adequate amount 
of lysis buffer and further pressed under homogenizer. After this further 
homogenization and lysis step, samples were kept on ice and vortexed every 5 
minutes for 30 minutes. Then, samples were centrifuged at 11000 rpm for 30 minutes 
and supernatants were transferred into new eppendorf tubes. Protein concentrations 
were measured by conventional Bradford assay with a spectrophotometer 
measurement at 595 nm.    
3.3.15 Western blotting  
Firstly, concentrations of the proteins were measured using conventional Bradford 
assay. All the absorbance values were taken using spectrophotometer at 595 nm 
wavelength. At the same time with the samples, different dilutions of already known 
protein concentration of bovine serum albumin (BSA) were measured with Bradford 
and the respective standard curve was calculated. This was used as a reference for the 
proteins with unknown concentration and thereby their concentrations were 
estimated by putting the absorbance values in the equation. 
After quantification of the protein concentrations of the samples, equal amounts of 
proteins were used to prepare loading mixtures. 25 to 40 µg of proteins were loaded 
into the gel according to the type of experiment. Loading samples were prepared by 
adding 4X NuPAGE LDS sample buffer, 10X denaturing agent (or 1M DTT), and 
ddH2O up to the final volume of 25 or 30 µl per well. Then, prepared loading 
mixtures were heated at 70 °C for 10 minutes before loading into the gel. 
In this study, NOVEX NuPAGE western blotting system was used for running the 
gels and transferring the proteins onto membrane. Gel concentrations and type of 
running buffers were chosen mainly according to size of the protein of interest. 10%, 
12% and 4-12% gradient Bis-tris precast gels were the type of gels used. And also, 
precast 3-8% gradient Tris-acetate gels were used for the detection of proteins with 
very high kDa values. Tris-acetate gels were run in the Tris-acetate running buffer. 
Furthermore, type of running buffer, either MES or MOPS, was also chosen 
depending on the size of the protein of interest. After running, proteins were 
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transferred onto Amersham HyBond ECL nitrocellulose or PVDF membranes with 
wet transfer protocol. Transfer buffer was prepared 1X (from 20X stock) with 10% 
methanol in ddH2O. Before preparation of wet transfer sandwich, all of the materials 
were soaked into transfer buffer, and especially PVDF membranes were extra 
activated in absolute methanol before soaked into transfer buffer. Transfer was done 
for 90-100 minutes (longer for proteins with very high kDa) under 30 V voltage 
applied. During the transfer, western blot tank was either kept in cold room or 
covered with ice.  
When the transfer was completed, the efficiency of transfer was tested by putting 
membrane into Ponceau S solution for 30 seconds. Then, Ponceau S solution was 
removed by washing membrane in ddH2O for a few minutes. Membranes were 
blocked with 5% non fat dry milk, 5% BSA or 2.5% QuickBlocker (Calbiochem, 
USA) in 0.2% TBS-Tween for 1 hour, 1 hour or 30 minutes, respectively. Short time 
blockings were done at room temperature, whereas over night blockings at +4 °C. 
After blocking, primary antibodies were prepared in non fat dry milk solution or 
BSA solutions and incubated for 1-2 hour(s) at room temperature or over night at +4 
°C. After primary antibody incubation, membranes were washed with 0.2% TBS-T 
three times for 5, 10, 10 minutes at room temperature. Then, horseradish peroxidase 
conjugated secondary antibodies; anti-mouse, anti-rabbit or anti-goat, were used as 
secondary antibodies according to the type of primary antibody used. Secondary 
antibody incubation was performed at room temperature for 1 hour. After this 
incubation, membranes were again washed three times for 5, 10, 10 minutes at room 
temperature on a shaker. Then, detections were done using chemiluminescent 
detection kits, ECL+ (Amersham, UK), West DURA (Thermo, USA), and West 
FEMTO (Thermo, USA), according to the manufacturer’s protocols, and  depending 
on the intensity of signal expected on the membrane. Finally, X-ray films were 
exposed to the emitted chemiluminescent light from the reaction of horseradish 
peroxidase and developed in X-ray developer. Time of exposure was chosen 
depending on the detection reagent and the specific antibody used against the protein 
of interest.                
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3.3.16 Real-time cell proliferation rate analysis with Roche xCELLigence 
system 
Real-time cell proliferation analysis was performed using Roche xCELLigence 
system. In order to detect proliferation, equal numbers of cells (4000) were seeded in 
E-96 96 well plates in a total volume of 200 µl. After 18 hours, real-time 
measurement was stopped and treatments were done immediately. Measurements 
were taken again in every 20 minutes for up to total 110 hours. Then, the 
corresponding cell index and proliferation curve data were saved.    
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4.  RESULTS 
4.1 FAM134B 
4.1.1 FAM134B at NCBI 
Family with sequence similarity 134, member B (FAM134B) is a protein coding 
gene in a family of family with sequence similarity 134. In addition to its first name, 
this gene is also known as JK1; FLJ20152; FLJ22155; FLJ22179. FAM134B has a 
NCBI gene ID 54463. Its location on the genome is chromosome 5, NC_000005.9. It 
is mapped to the region of 5p15.1 with the neighboring ZNF622 gene at upstream 
and MYO10 gene at downstream. FAM134B gene has two transcripts.  
NM_001034850.1 transcript is the transcript number 1, which represents the longer 
transcript and encodes the longer isoform. NM_019000.3 is the transcript variant 
number 2. Transcript 2 differs in the 5’ UTR and coding sequence compared to 
transcript 1. Isoform 2 encoded by transcript 2 has a shorter and distinct N-terminus 
compared to isoform 1. These two transcripts are produced by alternative splicing.     
 
Figure 4.2: Genomic region and transcripts of FAM134B 
Figure 4.1: Genomic context of FAM134B gene 
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Longer transcript, variant 1, consists of 9 exons while shorter transcript, variant 2, 
consists of 7 exons. Among these exons, the last 6 exons are identical in both 
variants while the first 3 exons of transcript 1 and the first exon of transcript 2 are 
unique for those transcripts.  
These two transcripts of FAM134B code for two different protein isoforms of 
FAM134B protein. Protein isoform 1 with accession number of NP_001030022 is 
the longer protein form consisting of 497 amino acids.  Protein isoform 2 with 
accession number of NP_061873 is the shorter form consisting of 356 amino acids.  
4.1.2 Domains of FAM134B 
In the ‘ensemble’ database, information for the domains of FAMN134B is given as 
the followings. FAM134B protein isoform 1 consists of one coiled coil domain at the 
C-terminal end of the protein, and two transmembrane domains located close to the 
N-terminal end of the protein. Similar to isoform 1, isoform 2 also has a coiled coil 
domain at the C-terminal end of the protein; whereas, isoform 2 consists of only one 
transmembrane domain close to the N-terminal end of the protein. Difference in the 
number of transmembrane domains of two isoforms is due to the fact that longer 
form has extra 3 exons at the 5’ end of the transcript encoding for amino acids 
representing an extra transmembrane domain for this isoform. Besides, isoform 1 has 
three low complexity regions on the protein, while shorter form has two of them.    
 
 
Figure 4.3: Domain representations of two isoforms of FAM134B  
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4.2 FAM134B in premature senescence  
Our group identified FAM134B gene as a replicative senescence associated gene. 
Previous studies on the relationship between FAM134B and replicative senescence 
came up with the results showing that FAM134B is not a cause of senescence; 
because its overexpression does not induce senescence in Huh7 cells (Tasdemir et al. 
unpublished data). However, increased FAM134B expression was detected in the 
replicative senescent clones in comparison with the immortal counterparts. A next 
question waiting to be answered was whether such an increase in FAM134B 
expression also takes place in premature senescence. 
4.2.1 FAM134B expression is not affected in adriamycin-induced premature 
senescence in Huh7 cells 
Adriamycin, also known as doxorubicin, is a drug used mainly in chemotherapy. 
Adriamycin is an inhibitor of topoisomerase II, and topoisomerase II inhibition 
results in the prevention of DNA synthesis. Adriamycin is also able to induce DNA 
strand breaks, leading to the activation of DNA damage response (Fornari et al., 
1994). Adriamycin treatment to Huh7 cells results in induction of premature 
senescence due to the accumulation of DNA damage leading to arrest in cell cycle. 
As seen in Figure 4.4, 72h 50ng/ml Adriamycin treatment to Huh7 cell causes cell 
cycle arrest, enlargement of the cytoplasm, and senescence-associated β-
galactosidase (SABG) positive phenotype in Huh7 cells.    
 
Figure 4.4: Adriamycin induces senescence in Huh7 cells, detected by SABG 
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In order to test whether there is a change in FAM134B expression in adriamycin 
induced premature senescence, Huh7 cells were treated with different concentrations 
of adriamycin for 3 days. Semi-quantitative RT-PCR result showing FAM134B 
expressions in each sample is given below.  
 
Figure 4.5: Adriamycin treatment does not change FAM134B expression in Huh7 cells.  
According to this result, expression of FAM134B isoform 1 is not affected by 
adriamycin treatment in Huh7 cells, regardless of the adriamycin concentration 
ranging from 50 ng/ml to 250 ng/ml. This result indicates that increased FAM134B 
expression in replicative senescent is not observed under another senescence 
condition, premature senescence induced by adriamycin.  
4.2.2 TGF-β treatment decreases FAM134B expression in Huh7 cells 
In addition to adriamycin, TGF-β is also used for induction of senescence in Huh7 
cells. TGF-β1 can induce senescence in HCC cell lines by activating p21(Cip1) and 
p15(Ink4b), resulting in the arrest of cells at G1 phase, independent of p53 status 
(Senturk et al., 2010). Therefore, in order to test if TGF-β induced senescence 
response is associated with increased expression of FAM134B, Huh7 cells were 
treated with 1 ng/ml and 5 ng/ml concentrations of TGF-β, which is sufficient for 
induction of premature senescence in Huh7 cells (Senturk et al., 2010).  
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Figure 4.6: TGF-β treatment decreases FAM134B expression in Huh7 cells 
Figure 4.6 shows the result of semi-quantitative RT-PCR experiment of FAM134B 
isoform 1 expression. According to this result, TGF-β treatment with different 
concentrations (1ng/ml or 5ng/ml) significantly decreases the expression of 
FAM134B isoform 1. Here, decrease in the expression is proportional to the 
concentration of the TGF-β treatment, indicating that decrease in FAM134B 
expression is possible not due to the induction of senescence phenotype but instead, 
FAM134B is somehow under a direct or indirect control of TGF-β pathway, because 
1 ng/ml TGF-β treatment for 3 days is sufficient to induce senescence in Huh7 cells 
(Senturk et al., 2010).       
 
Figure 4.7: TGF-β treatment causes a decrease in protein levels of FAM134B in HCC cells  
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Figure 4.7 shows a western blot result of change in FAM134B protein levels in 
response to 3 days TGF-β treatment in Huh7 and Snu387 HCC cell lines. According 
to these results, TGF-β treatment notably causes a decrease at protein levels of 
FAM134B in Snu387 poorly-differentiated HCC cell line. However, such a notable 
decrease cannot be seen in Huh7 cells, even though there is still a slight decrease at 
protein level in Huh7 cells.  
Together with the results of adriamycin treatment, these results briefly indicated that 
induction of premature senescence in distinct ways, either with adriamycin or with 
TGF-β, does not result in an increased FAM134B expression, unlike it has been 
detected in spontaneous replicative senescent model of Huh7 cells. 
4.3 FAM134B expression in HCC cell lines and tissues 
FAM134B is a newly identified gene and therefore there is not many published 
research referring to its expression in distinct cell types and tissues. Studies of Kurth 
et al. showed that FAM134B is predominantly expressed in mouse sensory and 
autonomic ganglia cells, while its other family members are predominantly expressed 
in central nervous system as well as liver, lung, and kidney (Kurth et al., 2009). 
These might present a clue about a tissue specific expression pattern of this gene in 
the organism. However, in order to obtain further information about the function of 
this gene at the tissue and cellular levels, cell line and tissue expression analysis of 
our laboratory models were performed at both mRNA level and protein levels.  
4.3.1 Detection of FAM134B mRNA levels in HCC cell lines 
FAM134B was firstly identified in a microarray study on a HCC cell line Huh7. 
Huh7 is one of the most commonly used HCC cell line model. However, there are 
other HCC cell lines with distinct mutations leading immortality or with different 
status of differentiation. In order to find out whether FAM134B expression is 
associated with any characteristics of these distinct hepatocellular carcinoma cell 
lines, FAM134B expression and protein level detection experiments were performed. 
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Figure 4.8: FAM134B mRNA levels in HCC cell lines 
Semi-quantitave RT-PCR results of FAM134B expression is shown in Figure 4.8. In 
this experiment, 15 different HCC cell lines were tested for both FAM134B isoform 
1 and isoform 2 mRNA levels in these cells. At the differentiation level, these 15 cell 
lines are grouped into two, namely well- and poorly-differentiated HCC cell lines. 
These subtypes of HCC were classified according to the markers of hepatocyte 
lineage and epithelial or mesenchymal characteristics. For instance, compared to 
well-differentiated cell lines, poorly-differentiated cell lines lost their hepatocyte 
characteristics and epithelial markers. Unlike poorly-differentiated cell lines, well-
differentiated ones remain their hepatocyte characteristics and they are not invasive 
(Yuzugullu et al., 2009). According to the results of this RT-PCR experiments from 
three different sets of HCC panel, FAM134B isoform 1 is predominantly expressed 
in poorly-differentiated cell lines in comparison to well-differentiated ones. Only 
exception is Hep40 well-differentiated cell line with high isoform 1 expression. On 
the other hand, isoform 2 is more likely to be expressed in well-differentiated HCC 
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cell lines, especially in Huh7, while most of the poorly differentiated cell lines are 
negative for isoform 2 expression, except Mahlavu and Focus. 
4.3.2 Detection of FAM134B protein levels in HCC cell lines  
In order to test whether distinct expression pattern of FAM13B isoform 1 is also 
represented at the protein level, western blot analysis of all 15 HCC cell lines was 
done.  
 
Figure 4.9: FAM134B protein levels in HCC cell lines 
 
Figure 4.10: Comparison of FAM134 protein levels in well- and poorly-differentiated HCC cell 
lines  
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According to the results shown in Figures 4.9 and 4.10, FAM134B protein levels are 
in a good correlation with the mRNA levels shown in Figure 4.8. FAM134B protein 
isoform 1 is detected at around 70 kDa marker. However, even though isoform 2 
mRNA was detected in some of HCC cell lines in RT-PCR experiment, protein 
isoform 2 cannot be detected in western blot experiment. Most of poorly 
differentiated cell lines, except Snu398, have substantial levels of FAM134B isoform 
1 protein, while all well-differentiated HCC cell lines, except Hep40, have low 
FAM134B isoform 1 protein. Figure 4.10 gives a better understanding of the relative 
protein levels in some well- and poorly-differentiated cell lines, loaded into the same 
gel. According to this result, FAM134B protein isoform 1 levels in poorly-
differentiated cells are considerably greater than that of well differentiated cells. In 
these western blot experiments, α-tubulin was used as a loading control.  
4.3.3 Detection of FAM134B protein levels in tissues 
In addition to detection of FAM134B in a group of HCC cell lines, FAM134B 
protein levels in distinct tissues were tested with western blot technique. These 
tissues were isolated from rat (Rattus norvegicus), homogenized and total cell lysates 
were collected using RIPA lysis buffer.   
 
Figure 4.11: FAM134B protein levels in rat tissues 
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Western blot result showed that FAM134B is mainly expressed in brain, testis, and 
liver. However, low FAM134B protein levels were also detected in spleen, kidney 
and ovary. On the other hand, FAM134B protein detected in the rat tissues consists 
of more than one form. Protein isoform 1, similar to human FAM134B isoform 1, 
has a protein weight of around 70 kDa, while another form, possibly a rat specific 
form, is below 40 kDa. 
4.4 FAM134B expression is down-regulated in cancer 
4.4.1 FAM134B in Chen liver data 
In 2002, studies of Chen et al. were published in an article titled ‘Gene expression 
patterns in human liver cancers.’ Liver tumor and non-tumor liver sample were 
collected and microarray gene expression analysis was done on 197 samples (Chen et 
al., 2002). Results of this expression analysis are publically available at ‘Oncomine’ 
database. Previous western blot experiment showed that FAM134B is expressed in 
normal liver of rat. To test if FAM134B expression varies in normal liver and HCC 
conditions, FAM134B expression was searched in Chen liver gene expression data. 
The box plot figure of FAM134B expression in normal liver and HCC samples, and 
calculated fold changes at ‘oncomine’ database are given below.   
 
Figure 4.12: FAM134B expression in Chen liver data 
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According to the Chen liver data, FAM134B expression is down-regulated in 
hepatocellular carcinoma samples in comparison with the normal liver samples. The 
fold change between HCC and normal is -2.769 fold, indicating that FAM134B 
expression is decreased more than 2 fold in HCC.  
4.4.2 FAM134B in Wurmbach liver data  
Studies of Wurmbach et al. was published in an article titled ‘Genome-wide 
molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.’ Gene 
expression profiles of 75 samples were analyzed. Among these 75 tissues, there were 
tissues representing each stem of liver carcinogenic process, including cirrhosis, 
dysplasia and HCC (Wurmbach et al., 2007). In order to check changes in FAM134B 
expression during different stages of molecular pathogenesis of HCC, FAM134B 
expression was searched on Wurmbach liver data at ‘oncomine’ database.  
 
Figure 4.13: FAM134B expression in Wurmbach liver data  
According to the analysis of FAM13B4 expression in Wurmbach liver data, 
FAM134B expression varies between different stages of HCC pathogenesis. 
Expression is high in normal liver samples, while being decreased in the initial stages 
of pathogenesis, namely cirrhosis and dysplasia. And, FAM134B expression is 
decreased far more in HCC. On the other hand, FAM134B expression is inversely 
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proportional to the grading of HCC cases, done in this study. According to the 
grading system of hepatocarcinogenesis, FAM134B expression is further decreased 
as going from grade 1 to grade 3 of HCC samples (data not shown).  
4.5 FAM134B expression is increased in response to ER stress 
Previous studies showed that FAM134B protein is localized onto cis-Golgi 
membrane (Kurth et al., 2009), or endoplasmic reticulum membrane (Tasdemir et al. 
unpublished data). In addition to its localization on ER membrane, FAM134B was 
firstly identified as senescence associated gene by our group (Ozturk et al. 
unpublished data). Because senescent cells starts secreting substantial amount of 
cytokines and growth factors, ER is forced to work at maximum capacity, resulting 
in induction of ER stress and UPR. Depending on these observations, to test the 
hypothesis that endoplasmic reticulum stress (ER stress) might affect the expression 
of FAM134B gene encoding for a ER resident protein, FAM13B4 expressions were 
tested in response to induction of ER stress with distinct ER stress inducers. 
4.5.1 Tunicamycin treatment increases FAM134B expression in Huh7 cells 
Tunicamycin is a mixture of antibiotics used as an agent for ER stress induction. It 
prevents the synthesis of N-linked glycoproteins in the ER, resulting in insufficient 
modifications leading to accumulation of these proteins and ER stress.  
 
Figure 4.14: Tunicamyin treatment causes an increase in FAM134B expression 
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According to the semi-quantitative RT-PCR results shown above, tunicamycin-
induced ER stress stimulates FAM134B expression in Huh7 cells. In this experiment, 
tunicamycin treatment was done for 24 h with different concentrations, ranging from 
100ng/ml to 2ug/ml. As seen in the figure, both isoforms 1 and isoform 2 expressions 
of FAM134B are increased in response to the treatment, with a gradual amplification 
in correlation with the concentration of the tunicamycin. Here, XBP-1 was used as a 
marker for ER stress. Under unstressed conditions XBP-1 mRNA is found in 
unspliced form, whereas, induction of ER stress results on splicing of XBP-1, 
producing a 26 bp shorter mRNA, which is used as a marker for ER stress (Lee et al., 
2002). GAPDH was used as an internal control for this semi-quantitative RT-PCR 
experiment.  
4.5.2  Dithiothreitol (DTT) treatment increases FAM134B expression in Huh7 
cells 
DTT is a common reducing agent, targeting disulfide bonds on proteins. Thanks to 
its reducing activity, DTT is also used as a common ER stress inducer (Li et al., 
2011). Therefore, in addition to tunicamycin treatment, DTT treatment was also 
tested as a different type of ER stress induction method in Huh7 cells. In this 
experiment, Huh7 cells were treated with the given concentration of DTT for 2 days. 
Cells were collected, total RNAs were extracted and cDNAs were synthesized from 
DTT treated samples. The figure below shows the RT-PCR results of the experiment.  
 
Figure 4.15: DTT treatment causes an increase in FAM134B expression 
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According to these results, DTT treatment causes an increase in total FAM134B 
expression in Huh7 cells. This results is promising if it is considered with the 
previous results showing that tunicamycin induced ER stress increases FAM134B 
expression. Detection of increased FAM134B expression upon DTT treatment, 
further supported the findings that FAM134B gene expression is responsive to ER 
stress, induced by distinct factors. 
4.5.3 Thapsigargin treatment increases FAM134B expression in Huh7 cells 
Thapsigargin is a reagent targeting SERCA pumps on the ER membrane. Therefore, 
thapsigargin treatment is a cause of ER stress through the mechanism affecting the 
calcium ion content of the ER (Denmeade and Isaacs, 2005). In order to test the 
effect of a different type of ER stress induction on FAM134B experiment, 
thapsigargin treatment was done Huh7 cells for 48 hours. Total mRNAs were 
isolated, cDNAs were synthesized and qRT-PCR analysis was done with total 
FAM13B4 primers.  
 
Figure 4.16: Thapsigargin treatment increases FAM134B expression in Huh7 cells  
According to this qRT-PCR result, FAM134B expression is increased more than 20 
fold in response to thapsigargin treatment for 48 hours, with a thapsigargin 
concentration of 2µM in DMSO. This result indicates that FAM134B expression is 
also up-regulated in response to calcium dependent ER stress in Huh7 cells.   
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4.5.4 Detection of changes at protein levels of FAM134B in response to ER 
stress 
Previous results indicated increased FAM134B mRNA levels in response to ER 
stress induction by tunicamycin, DTT or thapsigargin. Since these agents can induce 
ER stress through different mechanism, it is possible to state that FAM134B mRNA 
levels are up-regulated as a result of general ER stress, independent of the basis of 
stress induction. In order to detect changes at protein levels of FAM134B in response 
to ER stress induction, western blot experiments were done following ER stress 
induction in a few cell lines. Snu387 is a poorly-differentiated cell line with high 
FAM134B protein isoform 1 level, while Huh7 is a well-differentiated cell line with 
very low FAM134B protein compared to Snu387 (see Figure 4.10). These cell lines 
were treated with 500 ng/ml tunicamycin for different time points and changes in 
FAM134B protein levels were detected with immunoblotting experiments.  
 
Figure 4.17: Tunicamycin increases FAM134B protein levels in Snu387 cells  
 
Figure 4.18: Tunicamycin treatment does not affect FAM134B protein levels in Huh7 and Hela 
cells 
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Western blot results showed that in response to tunicamycin induced ER stress 
cannot induce up-regulation of FAM134B protein in all cell types. While FAM13B4 
protein levels were detected to be increased in Snu387 cells, in Huh7 and Hela cells, 
tunicamycin treatment did not cause a significant change in FAM134B at protein 
level. Similar different responses to ER stress induction at the level of FAM134B 
protein were also observed in Huh7 and FAM134B overexpressing Huh7 cells (see 
Figure 4.30).    
4.5.5 Change in FAM134B expression at G2-M and G1 stages of cell cycle 
In order to test whether FAM134B expression varies between stages of cell cycle, 
cell synchronization analysis was done using Huh7 cells. In brief, Huh7 cells were 
treated with nocadozole for 18 hours. After 18 hours, nocadozole was removed and 
samples were collected at every 5 hours. Semi-quantitative RT-PCR experiment was 
done to detect changes in the expression on FAM134B.  
 
Figure 4.19: FAM134B expression in synchronized Huh7 cells, detected by RT-PCR 
According to the synchronization results, FAM134B isoform 1 expression is 
considerably decreased in G2-M stage (0 hour) of Huh7 cells, compared to non-
synchronized Huh7 cells. And also, its expression is gradually increased following 
the removal of nocadozole, at 5
th
 and 10
th
 hours corresponding to G1 stage. On the 
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other hand, isoform 2 expression does not change as significant as isoform 1, only 
slightly increasing at 5
th
 hour compared to time 0. There is no change at expression 
level of FAM134B isoform 2 between non-synchronized Huh7 cell and G2-M phase 
synchronized cells.   
4.6 Differential expression of FAM134B in well- and poorly-
differentiated cell lines might be linked to their ER stress status 
Analysis of FAM134B expression in Chen and Wurmbach data sets showed that 
FAM134B expression is down-regulated in HCC compared to normal liver. 
Furthermore, within the subgroups of HCC, samples with higher grade have low 
levels of FAM134B expression in comparison with low grade samples (see Figures 
4.12 and 4.13). On the other hand, previous experiment showing FAM134B protein 
levels in rat tissues is likely to further support these findings, because FAM134B 
protein was detected in the liver of rat. Nevertheless, tissue results and microarray 
data results are not seem to be correlated with the results obtained from the detection 
of FAM134B in HCC cell line panel. According to these results, FAM134B was 
detected to be highly expressed in almost all poorly-differentiated cell lines, while 
expressions were low in well-differentiated HCCs. These controversial results 
showing that poorly-differentiated group (representing advanced stage of HCC) have 
higher FAM13B4 expression than that of well-differentiated group (representing 
early HCC) were actually explained by their status of ER stress.  
 
Figure 4.20: ER stress status of HCC cells, detected by sXBP-1 RT-PCR 
Figure 4.20 shows semi-quantitative RT-PCR results of XBP-1, which is an ER 
stress marker, in well- and poorly-differentiated cell lines. According to these results, 
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most of poorly-differentiated cells have an active UPR at basal level, without any 
treatment. However, well-differentiated HCC cells do not have an activated UPR, 
indicated by lack of sXBP-1.  
This observation is further supported by detection of ER stress response in these cell 
lines at the protein level. Other ER stress markers, phospho-PERK and phospho-
eIF2α were used as ER stress markers in this experiment. 
 
Figure 4.21: ER stress status of HCC cell lines, detected by western blot  
According to the western blot results, both of PERK branch ER stress markers, 
phospho-PERK and phospho-eIF2α are active in poorly-differentiated cell lines, 
while only a slight eIF2α phosphorylation is detected in well-differentiated cell lines. 
Unlike poorly-differentiated cell lines, well-differentiated cell lines do not show 
PERK phosphorylation at basal level, under untreated conditions. In this experiment 
α-tubulin was used as a loading control for the western blot experiment.  
4.7 FAM134B overexpression in Huh7 cells  
Our group previously produced stable clones of Huh7 cell lines overexpressing 
FAM134B isoform 1. In order for overexpression studies, Huh7 cells were preferred 
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because both of FAM134B transcript variants are low in this cell line. Stable ectopic 
overexpression of isoform 1 was done using CT-3XFLAG-FAM134B-iso1 (C-
terminal Flag tagged) and NT-3XFLAG-FAM134B-iso1 (N-terminal Flag tagged), 
and p3XFLAG-CMV10 vector as a control (Tasdemir et al. unpublished data). 
4.7.1 Testing FAMB134 overexpressing stable Huh7 clones 
Stable Huh7 clones overexpressing FAM134B isoform 1 and one control clone 
(CMV10-11) were tested with western blot using antibodies against FAM134B and 
Flag tag. Western blot results are given below. 
 
Figure 4.22: Testing FAM134B overexpressing clones, detected by western blot  
Figure 4.22 shows that all three clones are positive isoform 1 overexpressing clones 
of Huh7. Detection of the same band with Flag antibody shows that the band do not 
represent endogenous FAM134B protein but instead Flag-tagged FAM134B isoform 
1 expressed form the vector construct.  
4.7.2 FAM134B overexpression does not induce ER stress  
FAM134B expression is regulated by induction of ER stress. Treatments with 
tunicamycin, DTT or thapsigargin result in up-regulation of FAM134B expression in 
Huh7 cell lines (see Figures 4.14, 4.15, 4.16). These results contributed to the 
establishment of a new hypothesis that FAM134B overexpression itself might induce 
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a ER stress response, and activate UPR without any treatment. This hypothesis was 
tested by detecting ER stress marker XBP-1 in FAM134B overexpressing Huh7 cells 
(Huh7-FAM134B) and in control CMV10-11 Huh7 clones (Huh7-Control).  
 
Figure 4.23: Testing ER stress in Huh7-FAM134B clones, detected by RT-PCR 
This RT-PCR experiment showed that even though FAM134B expression is 
correlated with the ER stress response, overexpression of FAM13B4 does not 
contribute to induction of ER stress response under untreated conditions. In other 
words, FAM134B itself is not sufficient to activate IRE1 branch of UPR, functioning 
in the transduction of UPR signaling. 
4.7.3 FAM134B overexpression does not promote epithelial-to-mesenchymal 
transition in Huh7 cells 
Huh7 cells are categorized as well-differentiated cells, possessing epithelial like 
characteristics, such as E-cadherin expression, and hepatocyte markers (Yuzugullu et 
al., 2009). Epithelial like characteristic of Huh7 cells can be observed in in vitro 
culture. However, FAM134B overexpressing Huh7 clones were observed to be 
dissimilar to parental and Huh7-Control clones, having more spiked cell shape and 
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fibroblast like morphology (data not shown). On the other hand, studies of Ulianich 
et al. showed that tunicamycin and thapsigargin treatment to PC Cl3 thyroid 
epithelial cells triggers dedifferentiation, resulting a epithelial-to-mesenchymal 
(EMT) transition of these cells. This was found to be associated with downregulation 
of E-cadherin, upregulation of vimentin, alpha-smooth muscle actin (Ulianich et al., 
2008). In order to test such an EMT phenotype occurs in our FAM134B 
overexpressing Huh7 clones, epithelial and mesenchmal markers were aimed to be 
detected in these clones by immunofluorescence (IF) and RT-PCR experiments.  
 
Figure 4.24: Detection of EMT marker vimentin in Huh7-FAM134B cells by IF  
Results of IF experiment showed that vimentin expression is not considerably 
changed in Huh7-FAM134B (CT 1-14) cells compared to Huh7-Control (CMV 10-
11) cells, detected by low heterogeneous vimentin staining in both cases. 
 
Figure 4.25: Neither tunicamycin treatment, nor FAM134B expression induces EMT in Huh7 
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In addition to the immunofluorescence experiment, possible change in vimentin 
expression was tested by semi-quantitative RT-PCR experiment. According to the 
results shown above, FAM134B overexpression does not induce vimentin expression 
in Huh7 cells. Besides, unlike thyroid epithelial cells, Huh7 epithelial like cells does 
not undergo epithelial-to-mesenchymal transition upon tunicamycin treatment.  
4.7.4 FAM134B overexpression does not induce autophagy in Huh7 cells 
Dysregulation of ER homeostasis might cause induction of autophagy in order to 
facilitate the removal of unfolded proteins. Induction of ER stress by inducers, such 
as tunicamycin and DTT, also triggers autophagic response that can be detected by 
autophagy markers (Qin et al., 2010). In our Huh7 HCC model, activation of 
autophagy upon ER stress induction by tunicamycin was shown with a western blot 
experiment.  
 
Figure 4.26: Tunicamycin induces autophagy in Huh7 cells 
Figure 4.26 shows western blot results of autophagy induction upon tunicamycin 
treatment to Huh7 cells for 72 hours. Here, LC3B is a commonly used autophagy 
marker, making transition from its longer form I to shorter form II in the autophagic 
response (Barth et al., 2010).  As seen in the figure, both 1µg/ml and 2µg/ml 
tunicamycin treatment induces autophagy in Huh7 cells. α-tubulin was used as an 
equal loading control for the western blot experiment.  
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Tunicamycin induces autophagy in Huh7 cells. This fact made us hypothesize that 
FAM134B might be related to the induction of autophagy in response to ER stress. In 
order to test if FAM134B overexpression on Huh7 cells might affect autophagy in 
the lack of any ER stress induction, autophagy marker LC3B was checked in the 
Huh7-FAM134B clones and their control counterpart.  
 
Figure 4.27: FAM134B overexpression does not induce autophagy in Huh7 cells  
According to the results shown in Figure 4.27, FAM134B overexpressing Huh7 
clones, CT1-14, NT1-17 and NT1-18, does not differ in their autophagic response 
when compared to Huh7-Control (CMV10-11). On the other hand, in order to test if 
FAM134B protein isoform 2 can affect on autophagy, this form was overexpressed 
by transient transfection into Huh7 cells. According to the results, overexpression of 
FAM134B isoform 2 does not induce autophagy in Huh7 under untreated conditions. 
4.8 Induction of ER stress impairs proliferation of Huh7 cells 
Accumulation of unfolded proteins in the ER as a result of various factors described 
before damages ER homeostasis. Impaired homeostasis is signaled downstream 
through UPR to make cells undertake precautions against risky fates of the cells. 
Apart from triggering a signal to overcome the stress at the initial response, extended 
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and persistent stress is likely to be prevented by directing stressed cells to death. On 
the other hand, studies of Chiang et al. showed that N-glycosylation inhibitor 
tunicamycin treatment to Hep3B and HepG2 cells inhibits cell proliferation of these 
cells, resulting in the G1 arrest. This effect was further identified as associated with 
the decreases in the expression of key effectors of cell cycle, cyclin D1 and cyclin A 
(Chiang et al., 2008b). In order to test the effect of ER stress induction on Huh7 
cells, BrdU incorporation assay was performed and followed by detection of BrdU 
positivity with immunofluorescence experiment.  
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Figure 4.28: Tunicamycin inhibits proliferation of Huh7 cells, detected by BrdU IF 
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According to the results of BrdU incorporation assay following tunicamycin 
treatment to Huh7 cells, tunicamycin induced ER stress has an effect on proliferation 
capacity of Huh7 cells. Various concentrations of tunicamycin treatment showed that 
BrdU incorporation percentage is inversely proportional to the concentration of 
tunicamycin treatment, less BrdU positivity in response to higher tunicamycin 
treatment. Concentrations of 750ng/ml and 1µg/ml can decrease BrdU positivity of 
Huh7 cells by 60% after 48h or 72h treatments. On the other hand, these results 
showed that long term (48h or more) tunicamycin treatment is much more effective 
in comparison to 24 h treatment, with a difference of almost 40% more reduction. 
Furthermore, 100ng/ml concentration is not sufficient to decrease proliferation of 
Huh7 considerably, possibly due to the fact that Huh7 liver cancer cells are resistant 
to ER stress to some extent. 
Effects of tunicamycin on proliferation of Huh7 cells were also shown by detection 
of a key regulator of cell cycle. Retinoblastoma protein (pRb) is an important tumor 
suppressor, which is active when hypophosphorylated and able to inhibit cell cycle 
progression. Phosphorylation of Rb inactivates retinoblastoma protein resulting in 
the promotion of cell cycle (Vietri et al., 2006). Therefore, in order to determine the 
effect of tunicamycin treatment to cell cycle and proliferation of Huh7 cells, changes 
in pRb phosphorylation were showed by immunoblotting. Tunicamycin treatments 
were done with different concentrations and at different time point.  
 
Figure 4.29: Tunicamycin induces pRb activation and cell cycle arrest in Huh7 cells  
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As seen in Figure 4.29, tunicamycin treatment results in pRb dephosphorylation even 
after 24 hours. This result shows that following tunicamycin exposure, Huh7 cells try 
to stop cell cycle by activating pRb. pRb dephosphorylation is directly correlated 
with the inhibition of cell proliferation as detected in Figure 4.28 by BrdU 
incorporation assay.  
4.9 FAM134B increases sensitivity to thapsigargin induced 
apoptosis in Huh7 cells 
4.9.1 Western blot experiment 
Severe and prolonged ER stress causes induction of apoptotic response. The 
elements of UPR having role in apoptosis induction are reviewed at the introduction 
part (see Sec. 1.3.4). To test possible role of FAM134B protein in thapsigargin 
induced apoptosis response, experiments on detection of the apoptotic response were 
done, comparing responses of Huh7-FAM134B (CT1-14) and Huh7-Control 
(CMV10-11) clones.  
 
Figure 4.30: FAM134B increases sensitivity to thapsigargin induced apoptosis in Huh7 cells, 
detected by western blot   
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According the results shown in the Figure 4.30, FAM13B4 overexpressing Huh7 
cells (CT1-14) are more sensitive to thapsigargin induced apoptosis compared to 
control Huh7 cells under the same conditions. Upon thapsigargin treatment with the 
concentration of 2µM, PARP cleavage was detected after 24h in Huh7-FAM134B 
cells while it was not detected in control cells. Furthermore, at 48 hour, executioner 
caspase 3 is cleaved and activated in Huh7-FAM134B cells while this activation is 
not observed in Huh7 control cells. On the other hand, eIF2α phosphorylation levels 
also differ between these two clones. Its phosphorylation in Huh7-FAM134B cells is 
higher than that of Huh7-Control cells at 48h, indicating that PERK branch activation 
is more intense in FAM13B4 overexpressing Huh7 cells.  
Another critical observation obtained from this western blot results is that 
thapsigargin treatment to Huh7-Control cells slight increases the FAM134B protein 
level; whereas, treatment to Huh7-FAM134B cells causes a considerable 
upregulation at FAM134B protein level upon treatment with the same concentration 
and duration. According to this western blot result, and results obtained in Figures 
4.17 and 4.18, FAM134B protein level is amplified more significantly in cells that 
already have high FAM134B protein level, in response to ER stress induction. Put 
another way, if FAM134B protein level is low in a cell, ER stress induction does not 
substantially provide an increase at protein level of FAM134B. This might indicate a 
possible auto-regulation dependent control of FAM134B protein.    
4.9.2 Cell cycle analysis with flow cytometry 
In addition to western blot experiment, effects of FAM134B overexpression on 
thapsigargin induced apoptosis sensitivity was experimented by cell cycle analysis 
using propidium iodide. Propidium iodide is an intercalating reagent with a 
fluorescent activity. It can be used for detection of the DNA content due to its ability 
to bind DNA. In this study, propidium iodide staining of DNA was used for cell 
cycle analysis depending on the idea that fluorescent signal obtained from the dye 
corresponds to particular phase of cell cycle. Propidium iodide measurements and 
percentages of cell cycle analysis following thapsigargin treatment to Huh7-
FAM134B and Huh7-Control cells are shown below.  
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Figure 4.31: FAM134B increases sensitivity to thapsigargin induced apoptosis in Huh7 cells, 
detected by propidium iodide based cell cycle analysis  
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Figure 4.31 shows the flow cytometry results of propidium iodide staining in 
FAM134B overexpressing Huh7 and control huh7 cells after 2µM thapsigargin 
treatment for 48 hours. In these figures, M4 represents sub-G1 phase corresponding 
to apoptotic cells, while M1 represents G1, M2 represents S, and M3 represents G2 
phases of cell cycle. According to these results, thapsigargin treatment results in 
12.11% apoptotic cells in Huh7-Control cells. However, thapsigargin treatment to 
FAM134B overexpressing cells resulted in 46.89% apoptotic cells. On the other 
hand, thapsigargin treatment drastically decreases the percentage of cells at G2 
phase; whereas, percentage of cells at G1 phase was slightly increased in Huh7-
Control cells. These results indicate that Huh7-FAM134B cells are much more 
sensitive to the same concentration and duration of thapsigargin treatment. 
4.10 FAM134B overexpression impairs cell proliferation during 
thapsigargin induced ER stress  
Such an effect of FAM134B in apoptosis sensitivity was aimed to be further 
supported by possibly similar effect on cell proliferation. In order to test this 
hypothesis, real-time cell proliferation analysis was done with Huh7-Control and 
Huh7-FAM134B cells in response to thapsigargin treatment by using xCELLigence. 
 
Figure 4.32: FAM134B overexpression impairs proliferation of Huh7 cells during thapsigargin 
induced ER stress  
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Real-time cell proliferation assay showed that FAM134B overexpressing Huh7 cells 
are more sensitive to thapsigargin treatment, detected by immediate reduction in the 
cell index even 5 hours after treatment. Thapsigargin treatment starts affecting cell 
proliferation of Huh7-Control cells after approximately 10 hours following the 
treatment.  
These results come up with the interpretation that FAM134B protein increases the 
effectiveness of thapsigargin treatment, in ways that early and amplified apoptosis 
response, in addition to early and more significant decrease in proliferative capacity 
of the cells.  
4.11 FAM134B increases sensitivity to tunicamycin induced 
apoptosis in Huh7 cells 
4.11.1 Western blot experiment 
The findings that FAM134B overexpression affects both thapsigargin induced 
apoptosis and cell proliferation response led to experiment similar effect with a 
different ER stress inducer, tunicamycin. Therefore, Huh7-Control and Huh7-
FAM134B cells were treated with 5µg/ml tunicamycin for 48hours to compare their 
apoptotic responses to the same dose and duration.   
 
Figure 4.33: FAM134B increases sensitivity to tunicamycin induced apoptosis in Huh7 cells, 
detected by western blot   
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Western blot result revealed that FAM134B overexpression also increases sensitivity 
to tunicamycin induced apoptosis in Huh7 cells. Here, apoptosis is detected with 
cleaved PARP protein, while α-tubulin was used as a loading control. 
4.11.2 Cell cycle analysis with flow cytometry 
Increased sensitivity to tunicamycin induced apoptosis was shown using flow 
cytometry for cell cycle analysis of propidium iodide staining.  
  
 
Figure 4.34: FAM134B increases sensitivity to thapsigargin induced apoptosis in Huh7 cells, 
detected by propidium iodide based cell cycle analysis  
72 
 
According to the results given in Figure 4.34, M1 region corresponds to sub-G1 
cells, which are considered as apoptotic cells. Results showed that 5 µg/ml 
tunicamycin treatment caused 30% of Huh7-Control cells to follow apoptosis, while 
42% of Huh7-FAM134B cells entered apoptosis in response to the same treatment 
condition. Hence, it is possible to state that FAM134B also increases sensitivity to 
tunicamycin induced apoptosis in Huh7 cells, even though the difference of their 
percentages is not as great as difference detected in thapsigargin treatment.   
4.12 FAM134B overexpression impairs cell proliferation during 
tunicamycin induced ER stress  
Effect of FAM134B in tunicamycin treatment was further tested in a way that these 
cells are possibly influenced in terms of their proliferation efficiency during 
tunicamycin induced ER stress. Proliferative responses of Huh7-Control and Huh7-
FAM134B cells were experimented using xCELLigence real time system. 
 
Figure 4.35: FAM134B overexpression impairs proliferation of Huh7 cells during thapsigargin 
induced ER stress  
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Figure 4.35 shows real time proliferation of Huh7-FAM134B and Huh7-Control cells 
after treatment with various concentrations of tunicamycin. According to the results, 
cell indexes are the same at the time when treatments are done. Soon after 
treatments, Huh7-FAM134B cells’ cell indexes start decreasing, while that of Huh7-
Control cells still increases for a while. In brief, proliferation analysis indicated that 
not only in terms of apoptosis response, but also FAM134B is associated with the 
impairment of cell proliferation during tunicamycin induced ER stress response in 
Huh7 cells.    
4.13 FAM134B is likely to increase the severity of ER stress response 
Previous experiments showing stronger effects of thapsigargin on FAM134B 
overexpressing cells come up with questioning why these cells are more susceptible 
to thapsigargin treatment. It was shown that FAM134B overexpression itself does 
not suffice to induce an ER stress response (see Figure 4.23). However, abundant 
FAM134B protein might affect the influence of ER stress response if these cells are 
treated with a stress inducer. This hypothesis was tested by semi-quantitative RT-
PCR experiment following the treatment of Huh7-FAM134B and Huh7-Control cells 
with 2 µM thapsigargin for 48 hours. 
 
Figure 4.36: FAM134B increases the intensity of UPR following thapsigargin treatment  
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As seen in Figure 4.36, thapsigargin treatment to FAM134B overexpressing Huh7 
cells brings about increased activation of XBP-1 transcription factor compared to 
Huh7-Control cells, detected by more intense sXBP-1 band. This is at least a clue 
about the differential activation of IRE1 branch of UPR in the presence of abundant 
FAM134B protein. Hence, FAM134B overexpressing cells might trigger stronger 
UPR signaling, eventually leading to amplified cellular response in terms of 
apoptosis and proliferation. This hypothesis is further supported by the result 
showing that eIF2α phosphorylation is more intense in Huh7-FAM134B cells 
compared to Huh7-Control cells (see Figure 4.30). 
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5. DISCUSSION AND CONCLUSION 
This study primarily focused on the characterization of FAM134B in the contexts of 
hepatocellular carcinoma and endoplasmic reticulum stress. Starting from the 
originating point that FAM134B was found to be associated with senescence 
response (Ozturk et al. unpublished data), its relationships between replicative 
senescence, premature senescence, and endoplasmic reticulum stress were aimed to 
be experimented. 
5.1 FAM134B in the context of senescence  
After it was shown that immortal Huh7 HCC cells can be reprogrammed into 
spontaneous replicative senescence (Ozturk et al., 2006), the idea that tumorigenesis 
might be inhibited through induction of such a senescence phenotype became more 
plausible. On the other hand, analysis of significantly upregulated gene in response 
to spontaneous replicative senescence resulted in identification of FAM134B (Ozturk 
et al., unpublished data). First experiments on the identification of the relationship 
between FAM134B and replicative senescence came up with the understanding that 
FAM134B itself might not be a cause of senescence induction, detected by 
overexpression analysis (Tasdemir et al., unpublished data). Therefore, FAM134B is 
possibly associated with the senescence phenotype acquired as a result of 
spontaneous senescence response (Ozturk et al., 2006). However, in this study we 
aimed to find out if there is a direct correlation with the senescence phenotype of 
Huh7 cells and FAM134B expression. Thence, a possible change in FAM134B 
expression was tested in response to induction of a different type of senescence: 
premature senescence. 
Experiments on induction of premature senescence by adriamycin or TGF-β revealed 
that FAM134B expression detected to be upregulated in spontaneous replicative 
senescence is not directly associated with the senescence phenotype. Acquiring 
premature senescence by adriamycin treatment does not cause a significant change in 
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FAM134B expression. Additionally, induction of premature senescence by TGF-β 
treatment in Huh7 cells resulted in repression of FAM134B expression. These results 
firstly indicated that upregulation of FAM134B expression in replicative senescence 
of Huh7 is not related to the senescence phenotype, instead, possibly another cellular 
response appeared at this stage might have caused an increased FAM134B 
expression in these spontaneously replicative senescent clones of Huh7. Secondly, 
according to these results FAM134B is somehow a target of TGF-β signaling. TGF-β 
treatment resulted in a considerable decrease in FAM134B expression. This can be 
explained by a mechanism involving TGF-β pathway elements and control of 
FAM134B expression. 
On the other hand, this study provided the significant observations that FAM134B is 
associated with ER stress. Therefore, another explanation for the upregulation of 
FAM134B gene expression in spontaneous replicative senescence might be linked to 
stressed ER and activation of UPR in senescent clones. It has been known that 
chaperones and folding enzymes are negatively affected during aging, may be 
resulting in promotion of stress response (Naidoo, 2009). Because cellular 
senescence is associated with aging, increase in FAM134B expression might be 
linked to the dysregulated ER function as a result of aging. In addition, possibly not 
premature senescent cells but cells in replicative senescent stage obtain a 
characteristic of senescence associated secretory phenotype, causing secretion of 
massive amounts of cytokines (Davalos et al., 2010). Secretion of these cytokines 
demands their production and modification of in the ER, consequently leading to 
accumulation of a heavy load in the ER and triggering UPR as a result. 
5.2 Differential expression of FAM134B in tissues 
Our studies on detection of FAM134B protein levels in organs resulted in detection 
of FAM134B protein primarily in the brain, and also in liver and testis (see Figure 
4.11). This was not an unexpected result due to the fact that studies of Kurth et al. 
showed that FAM134B is predominantly expressed in neurons, detected by in situ 
hybridization (Kurth et al., 2009). Neurons and hepatocytes are cell types that are 
kept at quiescent G0 stage under normal circumstances. Together with these result, 
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especially considering neurons and hepatocytes, it is likely to interpret that 
FAM134B expression is mainly observed in cells with low proliferative capacity. 
One other significant support for this idea is the increased expression of FAM134B 
in replicative senescent clones of a cancer cell line, Huh7. As Huh7 cells lose their 
proliferative capacity, FAM134B expression is increased, in a concurrence with the 
high expression and low proliferative capacity in neurons and hepatocytes.  
5.3 Characterization of FAM134B in the context of hepatocellular 
carcinoma  
Characterization of FAM134B in the context of hepatocellular carcinoma refers to 
two different implications. One is characterization of FAM134B in the pathogenesis 
and distinct stages of HCC progression in vivo, and the other one is characterization 
in term of the differentiation status of HCC cell lines in vitro. 
Protein level analysis of FAM134B in the tissues (see Figure 4.11), and expression 
analysis in Chen and Wurmbach microarray data revealed that FAM134B is 
expressed in the normal liver (see Figures 4.12 and 4.13) (Chen et al., 2002; 
Wurmbach et al., 2007). However, according to these microarray data, expression of 
FAM134B is decreased as molecular pathogenesis of HCC progresses. In other 
words, expression is greater in normal liver than in cirrhotic liver and dysplasia, 
whereas, expression is lower in HCC compared to previous stages of pathogenesis. 
On the other hand, expression is also decreased in late stages of HCC, compared to 
early stages of HCC. These data propose that FAM134B is not associated with the 
carcinogenic characteristic of HCC. In fact, previous findings showing that 
FAM134B expression is associated with low proliferative capacity, are directly 
correlated with this statement.  
At the cellular level, our experiments showed that especially isoform 1 of FAM134B 
is expressed in poorly-differentiated cell lines, but not in well-differentiated cell 
lines, except in Hep40 (see Figures 4.8 and 4.9). This data does not seem to be 
correlated with the data obtained from molecular pathogenesis stages of HCC. Well-
differentiated HCC  cell lines are considered as epithelial or hepatocyte like cell lines 
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characterized as being positive for hepatocyte and epithelial markers; whereas, 
poorly-differentiated cell lines are categorized as mesenchymal-like cell lines that are 
positive for mesenchymal markers and have more metastatic characteristics 
(Yuzugullu et al., 2009). Therefore, poorly-differentiated cells lines are expected to 
represent late stages of hepatocarcinogenesis in vitro, while well-differentiated cells 
represent early stages of hepatocellular carcinoma. When these characteristics are 
taken into consideration, it is possible to state that in vivo and in vitro data are 
contradictory. 
Even though poorly-differentiated HCC cell lines are expected to represent later 
stages of HCC and they are not characterized with low proliferative capacity, 
FAM134B mRNA and protein levels are high in these cells. In this study, this 
contradiction was aimed to be solved by explaining this case not as a matter of 
differentiation or stage of pathogenesis, but in terms of possible other cellular factors 
affecting these cells. As a matter of fact, what was observed is that most of the 
poorly-differentiated cell lines have an active ER stress response at a basal level 
under untreated conditions (see Figures 4.20 and 4.21). Detection of basal spliced 
XBP-1 in some of the poorly-differentiated cells as well as the presence of basal 
level PERK and eIF2α phosphorylations are the indicators of, at least to some extent, 
active PERK and IRE1 branches of UPR in these cells. Our results showing that ER 
stress induction results in upregulation of FAM134B expression possibly serves for 
the most reasonable explanation for the link between high FAM134B expression and 
active ER stress response in these cells. 
5.4 Describing FAM134B in the context of ER stress  
Previous studies resulted in the detection of FAM134B localization on the 
endoplasmic reticulum membrane, co-localized with calnexin (Tasdemir et al., 
unpublished data); or on the cis-Golgi membrane, co-localized with giantin (Kurth et 
al., 2009). Considering these findings, FAM134B was aimed to be identified in terms 
of its response to ER stress. Thus, our results showed that induction of ER stress with 
diverse stress inducers, such as tunicamycin, dithiothreitol, or thapsigargin, provides 
increased FAM134B expression in Huh7 cells.  
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Increase in FAM134B expression in response to ER stress induction has also 
provided further support for other hypotheses. As being an ER stress responsive 
gene, its high expression pattern in poorly-differentiated HCC cell lines could be, 
and increased expression in replicative senescent Huh7 cells is likely to be explained 
by the presence of active ER stress response in these cells. Put in another way, the 
presence of FAM134B expression in these cells are due to the presence of an active 
ER stress response at basal level.  
FAM134B was detected to be associated with ER stress response. However, 
increased expression of FAM134B was identified only as a result of ER stress 
induction. Overexpression of FAM134B did not result in triggering a UPR in Huh7 
cells (see Figure 4.23). This shows that FAM134B is not a key factor in signal 
transduction from stressed ER to the downstream elements of UPR, unlike IRE1, 
ATF6 and PERK. However, as being an ER stress responsive gene, its expression is 
possibly regulated at transcription level by one of the downstream elements of UPR 
signaling.  
At the transcription level, FAM134B is regulated by UPR, showed by increased 
expression in response to ER stress induction. However, western blot experiments 
provided interesting results on protein levels of FAM134B in response to ER stress 
induction. According to these results, FAM134B protein levels are significantly 
upregulated in response to ER stress induction only in cells with high FAM134B 
protein levels. For instance, in Snu387 cell line, with high FAM134B protein level, 
tunicamycin treatment results in an increase of FAM134B protein level (see Figure 
4.17). However, tunicamycin treatment to Huh7 or HeLa cells does not cause an 
increase in protein levels of FAM134B in these cells (see Figure 4.18). This 
observation is further supported by another western blot result showing that 
thapsigargin treatment results in a drastic increase in the protein level of FAM134B 
in FAM134B overexpressing Huh7 clone CT1-14, while there is only a slight 
increase in protein level of FAM134B in Huh7 control clone CMV10-11 (see Figure 
4.30). These results might indicate that FAM134B is involved in a type of auto-
regulation loop, providing amplified protein production only in the case that the 
initial protein level is substantially high. Another possibility is that apart from control 
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of FAM134B at the transcription level, FAM134B protein levels are further 
controlled at the protein degradation level, which is inhibited when an ER stress is 
induced in a cell, resulting in the accumulation of FAM134B protein in response to 
ER stress.   
5.5 FAM134B and morphology of Huh7 cells 
In  in vitro culture, FAM134B overexpressing Huh7 cells were detected in an altered 
morphology, having spiky shapes on the cell membrane, a bit elongated cytoplasm 
and slightly separated colonization,  in comparison with the parental Huh7 and 
control Huh7 cells. These phenotypic changes seemed to be associated with 
mesenchymal-like characteristics. Therefore, this hypothesis was tested by detection 
of a mesenchymal marker vimentin by immunofluorescence and semi-quantitative 
RT-PCR experiments (see Figures 4.24 and 4.25). In addition, previously reported 
data of Ulianich et al., showing that ER stress induction by tunicamycin or 
thapsigargin in thyroid epithelial cells triggers EMT of these cells, was also tested 
using epithelial-like HCC cell line Huh7 (Ulianich et al., 2008). However, results 
revealed that there is no significant change in vimentin expression, when the cell 
overexpresses FAM134B. This result suggested that the cause of different cellular 
morphology of FAM134B overexpressing Huh7 cells is possibly due to unexpected 
changes during production of these stable clones.  
5.6 FAM134B and autophagic response 
It has been known that induction of ER stress leads to activation of autophagic 
response (Qin et al., 2010). In this study, firstly, we detected induction of autophagy 
in Huh7 HCC cells in response to tunicamycin treatment. Results showed that 
tunicamycin treatment for 72 hours triggers an autophagic response, observed by 
conversion of the autophagy marker LC3B, from its LC3B-I form to LC3B-II form 
(see Figure 4.26). Since FAM134B is responsive to ER stress induction, a possible 
relationship between FAM134B and autophagic response was tested. Comparison of 
autophagy in FAM134B overexpressing Huh7 clones and their control counterparts 
showed that FAM134B overexpression does not affect autophagy in Huh7 cells. 
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However, this experiment was done under untreated conditions. Therefore, rate of 
autophagic response in FAM134B overexpressing cells might change in response to 
ER stress induction by tunicamycin or thapsigargin.  
5.7 FAM134B as a mediator of ER stress induced apoptosis 
After detecting FAM134B as an ER stress responsive gene, we searched for a role of 
FAM134B in the context of ER stress response in Huh7 HCC cells. Thapsigargin and 
tunicamycin induced apoptosis responses of FAM134B overexpressing Huh7 cells 
and Huh7-Control cells were detected by western blot experiment, showing that 
Huh7-FAM134B cells are more sensitive to the same tunicamycin or thapsigargin 
treatments (see Figures 4.30 and 4.33). Propidium iodide based cell cycle analysis 
following these treatments also indicated significant differences between these clones 
in terms of rate of apoptotic cells in the population (see Figures 4.31 and 4.34). On 
the other hand, it was shown that triggering ER stress in Huh7 cells impairs cell 
proliferation (see Figure 4.28). Treatment of Huh7-FAM134B clones with 
tunicamycin or thapsigargin resulted in increased loss of proliferative capacity in 
these cells, in comparison with the Huh7-Control cells (see Figures 4.32 and 4.35). 
All these results pointed out a significant role of FAM134B protein in cells’ response 
to ER stress induction with chemicals.  
FAM134B increases sensitivity to ER stress induced apoptosis of Huh7 cells, at least 
when ER stress is induced by tunicamycin or thapsigargin. This might be further 
supported by apoptosis induction with other ER stress inducers. However, being 
sensitive to more than one chemical suggests that the mediator role of FAM134B in 
this response is not associated with a particular type of ER stress, such as calcium ion 
deprivation induced by thapsigargin, or lack of glycoprotein synthesis induced by 
tunicamycin. Therefore, it is possible to state that FAM134B has a general role 
affecting the response of the cell to the stressed ER. Increased stress response in 
FAM134B overexpressing Huh7 cells is further supported by detection of increased 
XBP-1 splicing following thapsigargin treatment (see Figure 4.36). This result 
suggested that, at least activation of IRE1 branch of UPR might be influenced by the 
abundance of FAM134B protein. However, not only IRE1 arm of UPR, but also 
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activation of the PERK arm of UPR is also affected by the overexpression of 
FAM134B protein in Huh7 cells, detected by increased eIF2α phosphorylation in 
FAM134B overexpressing cell compared to control cells (see Figure 4.30). 
Increased sensitivity to ER stress in FAM134B overexpressing cells might be 
explained by its possible function in ER structure. FAM134B structure is predicted to 
have two hydrophobic segments flanked by hydrophilic loop, similar to the structure 
of reticulon proteins (Kurth et al., 2009; Voeltz et al., 2006). Reticulons undertake a 
role in shaping the ER membrane by inserting their hydrophobic domains into the ER 
membrane, shaping the curvature of ER membrane (Voeltz et al., 2006). On the other 
hand, studies of Shuck et al. showed that UPR signaling controls the expansion of 
ER membrane via generation of ER sheets. Furthermore, expansion of ER membrane 
relieves the stress in the ER independent of chaperone protein levels (Schuck et al., 
2009). Based on these findings, one hypothesis is that after induction of ER stress 
with tunicamycin or thapsigargin, cells try to expand their ER membrane and 
increase ER size in order to relieve the stress in the ER. However, overexpression of 
a reticulon-like protein FAM134B in the ER membrane might inhibit expansion of 
ER size following stress induction, thereby preventing the alleviation of the ER 
stress. This is likely to result in sensing increased ER stress. This might also explain 
why Huh7-FAM134B cells are more sensitive to ER stress induced apoptosis. Due to 
the prevention of ER size expansion, UPR response is amplified, triggering more 
severe stress response and eventually apoptosis. 
Another hypothesis might be related to the direct involvement of some reticulon 
proteins in apoptosis. Studies of Tagami et al. suggested that Reticulon 4B (RTN4B) 
protein is able to interact with anti-apoptotic protein Bcl-2. This interaction results in 
the localization of Bcl-2 on the ER membrane, resulting in the prevention of its anti-
apoptotic activity (Tagami et al., 2000). As being a reticulon-like protein, FAM134B 
might have such a function on the ER membrane, causing accumulation of Bcl-2 
protein on the ER membrane, thereby, inhibiting its anti-apoptotic activity on 
mitochondria. In this case, FAM134B overexpression itself might not be sufficient to 
trigger apoptosis; whereas, the help of an ER stress inducer and prolonged exposure 
might facilitate the apoptotic response in FAM134B overexpressing cells. 
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5.8 FAM134B in the pathogenesis of HCC  
The basis of HCC is the accumulation of excess tissue damage in hepatocytes, and 
later on, the acquisition of proliferation capacity. Our results showed that FAM134B 
is associated with ER stress induced apoptosis, and that FAM134B is expressed in 
normal liver.  When these are taken into consideration, FAM134B might have a role 
in the accumulation of tissue damage in liver, especially in response to the ER stress. 
Therefore, FAM134B might be linked to the pathogenesis of hepatocellular 
carcinoma. 
It is known that at least two of the major risk factors of hepatocellular carcinoma are 
associated with ER stress. One of them is the hepatitis C virus infection. HCV 
infection is a major cause of chronic hepatitis, which is likely to result in cirrhosis 
and HCC. HVC infection causes abundant expression of NS5A in the ER, leading to 
ER stress and activation of STAT-3 and NF-ĸB in hepatocytes (Waris et al., 2002). 
Another risk factor, diabetes, is also associated with ER stress in the liver. The link is 
primarily due to the accumulation of free fatty acids in the liver and acquisition of 
insulin resistance in the liver (Maclaren et al., 2007). Studies of Ozcan et al. showed 
that ER stress is a key characteristic of insulin resistance and type 2 diabetes at both 
cellular and organismal levels (Ozcan et al., 2004). Taken together, our results 
indicating that FAM134B is a factor in ER stress induced apoptosis can be 
interpreted in a way that FAM134B contributes to the liver pathogenesis during the 
early stages of HCC. Even though HCV and diabetes are the main factors resulting in 
ER stress in hepatocytes, hepatocytes expressing FAM134B might become more 
susceptible for accumulation of tissue damage at these stages, due to the fact that 
FAM134B amplifies the apoptotic response in ER stress conditions.  
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6. FUTURE PERSPECTIVES 
This study has primarily revealed that FAM134B is a significant ER stress response 
gene, and it is associated with apoptosis response resulting from the ER stress. Even 
though results given in this study have provided preliminary data for the 
establishment of this information, further studies are still required to support the 
hypotheses suggested here, and to further examine the role of FAM134B in the 
context of ER stress and hepatocellular carcinoma.  
First of all, the findings showing that FAM134B is an ER stress response gene could 
be additionally supported by inducing ER stress with other chemicals such as 
Brefeldin A. On the other hand, this study only involves experiments with 
thapsigargin and tunicamycin induced apoptosis detection in Huh7 cells. Apoptosis 
induction and sensitivity to ER stress induced apoptosis experiments in Huh7-
FAM134B and Huh7-Control cells could be done using different ER stress inducers 
such as DTT and Brefeldin A. Moreover, apoptosis sensitivity could be further 
detected by other apoptosis detection methods, such as TUNEL or Annexin V 
immunofluorescence assays. 
Furthermore, studies on ER stress related characterization of FAM134B should be 
supported by knock down experiments. This might involve downregulation of 
FAM134B expression by shRNA or siRNA approaches. The fact that FAM134B 
increases the sensitivity to ER stress induced apoptosis should be shown in terms of 
its vice versa effect, when FAM134B protein level is decreased in a cell line, which 
has a high endogenous FAM134B protein level.  
FAM134B is an ER or cis-Golgi membrane protein. Its knockdown results in 
reduced cis-Golgi size in N2a cells (Kurth et al., 2009). These findings suggest that 
FAM134B might have a structural role in endoplasmic reticulum membrane too. 
This hypothesis could be tested by knock down studies of FAM134B, followed by 
detection of changes in ER size by confocal microscopy. On the other hand, ER size 
changes should be experimented in these cells in response to ER stress induction. 
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Besides, changes in the ER size of FAM134B overexpressing and control Huh7 cells 
should be detected following the ER stress induction by thapsigargin or tunicamycin. 
Studies of Schuck et al. showed that alleviation of ER stress in response to chemical 
treatment is also related to the expansion of ER size (Schuck et al., 2009). If 
FAM134B is somehow able to inhibit the ER membrane expansion, it is possible to 
detect a deficiency in expansion of ER size in FAM13B4 overexpressing Huh7 cells. 
FAM134B is a reticulon like protein. It was shown that reticulon 4 B protein has a 
role of binding to Bcl-2 anti-apoptotic protein, causing it to localize on the ER 
membrane and inhibiting its anti-apoptotic function on the mitochondria (Tagami et 
al., 2000). FAM134B may also have a similar function. Therefore, interating partners 
of FAM134B should be detected by immunoprecipitation experiments. On the other 
hand, detection of interacting partner may result in identification of a differetn role of 
FAM134B on the ER, such as transport between ER and Golgi.  
Our results showed that FAM134B is expressed in normal liver. And, according to 
the results of other studies, FAM134B expression decreases during the pathological 
stages of HCC in the liver (see Figures 4.12 and 4.13). These findings should be 
further supported by detection of FAM134B in the tissue samples of different 
pathological stages. These experiments can be done by immunohistochemistry or by 
western blot techniques in order to detect the changes at the protein level.  
Mutation in FAM134B gene is associated with a neurodegenrative disease (Kurth et 
al., 2009). However, in vivo effects of FAM134B deficiency has not been 
experimented in mouse models. Therefore, it might be worth to study mouse knock 
out model of FAM134B and its relationship with the development of liver 
pathogenesis. According to the results we obtained in our studies, FAM134B knock 
out mouse might be less susceptible for development of HCC under the effect of 
same risk factors, such a HCV infection.     
Here, we only used in vitro HCC model in this study. Similar effects of FAM134B 
might be associated with the other cancer types too. Therefore, such overexpression 
analysis and also knock down analysis could be done in different cancer types.  
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